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Introduction 
Purpose of This Guide 
This guide is intended to provide 
nurses (including Registered Nurses 
(RNs), Licensed Practical Nurses
(LPNs), and Nurse Practitioners 
(NPs)) with general information about 
buprenorphine products—Suboxone® 
(buprenorphine and naloxone) and
Subutex® (buprenorphine)—for the 
pharmacological treatment of opioid 
addiction. The guide can also serve as
a resource to help nurses working with 
community physicians to improve
treatment outcomes for individuals 
receiving office-based treatment for 
opioid addiction. 
Providing comprehensive services in
conjunction with medication is the 
most effective method of treating
opioid addiction. It is important that 
buprenorphine be administered in
conjunction with behavioral therapy 
and psychosocial support to ensure 
medication compliance and to increase 
patient functioning (NAADAC, 2002).
The ultimate success of buprenorphine 
will depend on its integration into a 
broader continuum of health care 
services that includes counseling for 
patients with substance use disorders.  
Nurses in all settings may be called 
upon to work with individuals 
undergoing treatment for opioid
addiction with buprenorphine 
products and with physicians to
improve treatment outcomes by
providing behavioral treatment and
counseling.
Learning Objectives 
The guide is intended to fulfill the 
following objectives:  
1. To provide nurses with general
information on the pharmacology, 
safety profile, adverse effects, 
interactions, cautions,
contraindications, and abuse 
potential of buprenorphine 
products (note: Suboxone® and 
Subutex® are the registered names 
of these products). 
2. To increase nurses’ factual 
knowledge on protocols for the use 
of buprenorphine products in
medically supervised withdrawal 
(detoxification) and maintenance 
treatment services. 
3. To help nurses, in conjunction with
authorized physicians, design 
strategies for providing 
comprehensive physical and
psychosocial assessments, 
treatment monitoring, and
appropriate referral for opioid
addiction and co-occurring medical 
and psychiatric conditions. 
4. To provide comprehensive and 
practical guidance for patient 
screening, assessment, induction, 
stabilization, and prevention of
precipitated withdrawal in 
medically supervised withdrawal 
(“detoxification”) or maintenance
treatment services. 
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5. To educate nurses about effective 
communication, assessment of
patients’ readiness to change, and
appropriate motivational
enhancement interventions to 
ensure that psychosocial 
counseling is delivered
concurrently with pharmacological 
interventions. 
6. To enhance addiction recovery 
management by educating nurses 
about stigma, patient 
empowerment and the recovery 
partnership, evidence-based
practices, the application of
technology, and the importance of 
ongoing patient monitoring and 
support. 
2
 Background 
Data 2000: Legislative 
Authority for Buprenorphine 
Treatment  
Federal legislation—the Drug 
Addiction Treatment Act of 2000 
(DATA 2000)—changed addiction 
treatment in the United States by 
permitting office-based physicians to 
treat addiction to opioid (narcotic) 
drugs, such as heroin and many 
prescription pain relievers, with 
Schedule III–V narcotic medications 
approved by the U.S. Food and Drug 
Administration (FDA). Under the 
statutory provisions of DATA 2000, 
physicians who wish to prescribe (or 
dispense) approved medications for 
opioid therapy must first obtain a 
waiver that releases them from the 
separate registration requirements of 
the Narcotic Addiction Treatment Act 
of 1974 and its enabling regulations 
for the provision of opioid addiction 
treatment. (One enabling regulation is 
Title 42 of the Code of Federal 
Regulations (CFR), Part 8: Opioid 
Drugs in Maintenance and 
Detoxification Treatment of Opiate 
Addiction; Final Rule.) The 
Department of Health and Human 
Services (HHS) responsibility for the 
waiver program is administrated by 
the Substance Abuse and Mental 
Health Services Administration 
(SAMHSA) in HHS and follows certain 
criteria specified in DATA 2000 by 
which physicians’ qualifications are 
considered before a waiver is issued. 
Before prescribing Suboxone® or 
Subutex®, qualified physicians must 
notify the Secretary of HHS of their 
intent by submitting applications for a 
waiver. To obtain a DATA 2000 
waiver, a physician must send 
SAMHSA a notification of intent to 
begin practicing this form of therapy. 
The notification of intent may be 
submitted online at the SAMHSA 
Buprenorphine Web site 
(http://buprenorphine.samhsa.gov) or 
mailed or faxed to SAMHSA using a 
notification form, SMA-167, that can 
be downloaded from the Web site. The 
notification of intent must contain 
information on the physician’s 
qualifying credentials, training 
certificates, and other information. 
Each physician must certify that the 
physician has the capacity to refer 
addiction patients for appropriate 
counseling and other 
nonpharmacological therapies. 
Physicians must also certify that they 
will use certain treatment medications 
and adhere to patient limits. 
Physicians’ Qualifications 
Under DATA 2000, prescription of 
buprenorphine products (Suboxone® or 
Subutex®) for the treatment of opioid 
addiction is limited to physicians who 
meet qualifying requirements. 
Physician Assistants (PAs), Nurse 
Practitioners (NPs), and Advanced 
Practice Nurses (APNs) may not 
prescribe buprenorphine products for 
the treatment of addiction even in 
 3 
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States that allow them to prescribe 
Schedule III, IV, or V drugs.  
Physicians may be considered 
qualified to prescribe buprenorphine 
products if they:  
• Meet at least one of the following 
training requirements: 
– Hold a subspecialty board 
certification in addiction 
psychiatry from the American 
Board of Medical Specialties; 
– Hold a certification from the 
American Society of Addiction 
Medicine (ASAM);  
– Hold a subspecialty board 
certification in addiction medicine 
from the American Osteopathic 
Association;  
– Have completed not less than 
8 hours of authorized training on 
the treatment or management of 
opioid-dependent patients. This 
training may include classroom 
situations, seminars at 
professional society meetings, 
electronic communications, or 
other media;  
• AND meet both of the following 
criteria: 
– Have the capacity to provide or to 
refer patients for necessary 
ancillary services, such as 
psychosocial therapy; and  
– Agree to treat the applicable 
numbers of patients (30 or 100) in 
their individual or group practice 
(DATA 2000; Office of National 
Drug Control Policy 
Reauthorization Act of 2006 
(ONDCPRA—Public Law 
109-469)).  
Originally, waivered physicians were 
limited to treating no more than 
30 patients with approved 
buprenorphine products at any one 
time under DATA 2000, and physician 
group practices were also limited to 
30 patients. The physician group 
practice limit was eliminated by 
Public Law 109-56, effective August 2, 
2005, so that each physician in a 
group practice, like a physician in solo 
practice, was permitted to treat up to 
30 patients at any given time.  
Under the ONDCPRA, effective 
December 29, 2006, physicians who 
meet the following criteria may notify 
the Secretary of HHS of their need 
and intent to treat up to 100 patients 
at any one time. To meet the 
requirements, (1) the physician must 
currently be qualified under DATA 
2000, (2) at least 1 year must have 
elapsed since the physician submitted 
the initial notification for 
authorization, (3) the physician must 
certify his or her capacity to refer 
patients for appropriate counseling 
and other appropriate ancillary 
services, and (4) the physician must 
certify that the total number of 
patients at any one time will not 
exceed the applicable number.  
The SAMHSA Buprenorphine 
Information Center has information 
specialists available to answer 
questions about buprenorphine and 
DATA 2000 on weekdays from 
8:30 a.m. to 5:00 p.m., Eastern time. 
The Information Center may be 
reached by telephone at 866–287–2728 
or by e-mail at 
info@buprenorphine.samhsa.gov. 
SAMHSA will communicate with the 
Drug Enforcement Administration 
(DEA) in the Department of Justice, 
review the notification, and inform the 
DEA whether or not the physician is 
qualified as required by DATA 2000. 
The DEA will issue a unique 
4 
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identification number that indicates 
that the physician is qualified under 
DATA 2000. The physician then will 
be authorized to dispense and/or 
prescribe under the authority of his or 
her DEA practitioner registration. 
CSAT will send the physician a letter 
with the newly assigned DEA 
identification number. A new DEA 
registration certificate will be issued 
to the physician that documents the 
new DEA number that must be 
written on buprenorphine 
prescriptions as well as the original 
DEA registration number assigned to 
the physician.  
DATA 2000 only permits physicians to 
prescribe and dispense approved 
opioid medications for the treatment 
of addiction. At this time, only 
Subutex® (buprenorphine) and 
Suboxone® (buprenorphine/naloxone) 
have been approved for office-based 
treatment. Physicians are specifically 
prohibited from delegating prescribing 
opioids for detoxification and/or 
maintenance purposes to 
nonphysicians (i.e., Advanced Practice 
Nurses (APNs), Nurse Practitioners 
(NPs), and Physician Assistants 
(PAs)). 
Since 2001, SAMHSA has been 
responsible for monitoring and 
regulating the use of opioid 
medications in treatment with 
methadone and buprenorphine. Since 
the implementation of DATA 2000, 
SAMHSA can provide office-based 
physicians a waiver to prescribe 
Schedule III, IV, and V medications 
such as Subutex® (buprenorphine) and 
Suboxone® (buprenorphine and 
naloxone) in their office settings 
(CSAT, 2004).  

  
 
 
 
 
 
 
 
 
  
 
 
 
 
Buprenorphine and the Role of the 

Nurse 
Currently, advanced practice nurses and 
NPs may not prescribe or dispense 
buprenorphine products for the treatment
of addiction even in States that allow them 
to prescribe scheduled medications under 
certain controls, supervisions, and other 
restrictions. This guide will highlight the 
addictions management skills of nurses and
promote a mutually respectful team 
environment in which nurses and 
physicians collaboratively work to improve
the care provided to individuals who are 
addicted to opioids. This care may include 
assessment, induction, stabilization, 
maintenance, monitoring, addiction 
counseling, and relapse prevention. 
The nurse’s roles with patients 
receiving buprenorphine for the
treatment of addiction (1) may be 
subject to State practice regulations and
(2) may include, but not be limited to:  
• Conducting screening, assessment, 
treatment monitoring, counseling, 
and supportive services; 
• Educating patients, their family
members, or other supportive 
individuals about buprenorphine
therapy as well as risks, benefits, 
potential side effects, interactions, 
program requirements, consents,
and treatment contracts; 
• Involving patients in the 
development of the treatment plan, 
and working with the patient and 
the interdisciplinary team to
individualize the plan for meeting 
the patients’ needs; 
• Enhancing treatment readiness,
supporting treatment completion,
ensuring safety, and promoting 
sustained recovery outcomes for 
individuals undergoing buprenorphine 
treatment for opioid addiction;
• Improving access, identifying 
community resources, and providing 
information about them; and
explaining reimbursement options for 
office-based buprenorphine treatment;  
• Assisting patients in accessing care 
elsewhere when the present practice
is not a suitable option for them; and 
• Assisting patients in accessing other 
treatment options as needed (e.g.,
day treatment, residential, 
outpatient, methadone detoxification
or maintenance, etc.). 
More detailed information is available 
in Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of
Opioid Addiction, SAMHSA’s 
Treatment Improvement Protocol
(TIP) #40 (CSAT, 2004). The
guidelines cover screening, 
assessment, and diagnosis of opioid 
dependence and its associated
problems. The guidelines also contain 
detailed protocols for the use of
buprenorphine under a variety of
clinical scenarios, including the use of 
buprenorphine with patients who are
experiencing co-occurring pain or 
psychiatric disorders, or chemical 
dependency involving more than one 
substance. 
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General Opioid Pharmacology 
Opioid Receptors 
Opioid receptors are molecules on the 
surface of cells to which opioid 
compounds attach and through which 
they exert their effects. Three different 
types of opioid receptors are present in 
the brain: mu, kappa, and delta. Two of
these opioid receptors (mu and kappa) 
are also found in the spinal cord and
mediate pain transmission at this level
of the nervous system, i.e., from the 
periphery to the brain. The receptor 
most relevant to opioid abuse and 
treatment is the mu receptor. It is 
through activation of the mu receptor
that opioids exert the majority of their 
analgesic (pain-relieving property),
euphorigenic (euphoria or “high”), and 
addictive effects (CSAT, 2004).
Although the mu receptor is, as noted, 
the most relevant to opioid abuse and
treatment, the kappa and delta 
receptors are also responsible for opioid 
addiction. 
The Functions of Opioids at Receptors 
Opioids can interact with receptors in
different ways. Three types of
drug/receptor interactions are agonists 
(or full agonists), antagonists, and 
partial agonists (CSAT, 2004). 
Full Agonists 
Drugs that activate receptors in the 
brain are termed agonists. Agonists 
bind to receptors and turn them on,
thereby producing an effect in the
organism. Full mu opioid agonists
activate mu receptors. Opioids with
the greatest abuse potential are full
agonists (e.g., morphine, heroin, 
methadone, oxycodone,
hydromorphone) (CSAT, 2004). 
Antagonists 
Antagonists also bind to opioid
receptors, but instead of activating
receptors, they effectively block them. 
An antagonist is like a key that fits in
a lock but does not open it and
prevents another key from being 
inserted to open the lock. Examples of
opioid antagonists are naltrexone and
naloxone (CSAT, 2004). 
Partial Agonists 
Partial agonists possess some of the 
properties of both antagonists and full
agonists. Partial agonists bind to 
receptors and activate them, but not to
the same degree as do full agonists. At
lower doses and in individuals who are 
not dependent on opioids, full agonists 
and partial agonists produce effects that
are indistinguishable. As doses are 
increased, both full and partial agonists 
produce increasing effects. At a certain 
point, however, the increasing effects of
partial agonists reach maximum levels
and do not increase further, even if
doses continue to rise—”the ceiling 
effect.” As higher doses are reached,
partial agonists can act like
9 
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antagonists—occupying receptors but 
not activating them (or only partially
activating them), while at the same 
time displacing or blocking full agonists 
from receptors. Buprenorphine is an
example of a mu opioid partial agonist 
(CSAT, 2004). 
Consequences of Repeated 
Administration and Withdrawal of 
Opioid Drugs 
The repeated administration of a mu
opioid agonist results in tolerance and 
dose-dependent physical dependence. 
Tolerance is characterized by a
decreased subjective and objective
response to the same amount of
opioids used over time or by the need
to keep increasing the amount used to
achieve the desired effect. In the case 
of abuse or addiction, the desired 
effect typically is euphoria. Physical
dependence is manifested as a set of 
withdrawal signs and symptoms in 
response to reduction, cessation, or 
loss of the active compound at
receptors (withdrawal syndromes). 
Typical signs and symptoms of the 
opioid withdrawal syndrome include 
lacrimation (tears), diarrhea, 
rhinorrhea, piloerection (goose flesh),
yawning, cramps and aches, pupillary 
dilation, and sweating. In an 
individual who otherwise is in good
general health (e.g., with no history of
significant cardiovascular disease),
opioid withdrawal is not life
threatening. Patients with
cardiovascular disease or other severe 
conditions will need comanagement 
involving the appropriate specialist, as
well as consultation with an addiction 
specialist (CSAT, 2004). The primary
distinguishing characteristic that 
differentiates dependence from 
addiction, as outlined in the 
Diagnostic and Statistical Manual IV
(Text Revision) (DSM-IV-TR) (APA, 
2000) criteria, is the behavioral
component of continued use despite
negative consequences. 
Two types of withdrawal are
associated with mu opioid agonists: 
spontaneous withdrawal and
precipitated withdrawal.  
Spontaneous Withdrawal 
Spontaneous withdrawal can occur
when an individual who is physically 
dependent on mu agonist opioids (e.g., 
has been using opioids on a daily
basis) suddenly discontinues that 
opioid use. It also can occur if an
individual who is physically
dependent markedly decreases his or
her daily opioid use. In an individual
who is physically dependent on heroin,
spontaneous withdrawal usually
begins 6–12 hours after the last dose
and peaks in intensity 36–72 hours 
after the last use. The spontaneous
withdrawal syndrome from heroin
lasts approximately 5 days, although a
milder, protracted withdrawal may 
last longer. Other short-acting opioids, 
such as oxycodone and hydrocodone, 
have kinetic profiles that are similar 
to heroin, and the time course of 
spontaneous withdrawal for these
agents should be similar to that 
documented for heroin. Opioids with 
longer half-lives have a longer period
before the onset of spontaneous
withdrawal (e.g., 24–72 hours for
methadone) and a longer period before 
peak withdrawal is experienced 
(CSAT, 2004). 
Precipitated Withdrawal 
Precipitated withdrawal usually 
occurs when an individual who is
physically dependent on opioids is
administrated an opioid antagonist. In 
10
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an individual who is not physically
dependent on opioids, the acute
administration of an antagonist 
typically produces no effects. In an 
individual who is physically
dependent on opioids, however, an
antagonist produces a syndrome of
withdrawal that is qualitatively
similar to that seen with spontaneous
withdrawal (although the onset is 
faster and the syndrome is shorter,
depending on the half-life of the
antagonist). One way to conceptualize 
precipitated withdrawal is that the 
antagonist displaces agonists from 
receptors, but because the antagonist
does not activate the receptor, there is
a net decrease in agonist effect,
resulting in withdrawal. It is also 
possible for partial agonists to
precipitate withdrawal. If an 
individual who is physically
dependent on opioids receives an acute 
dose of a partial agonist, the partial
agonist can displace the full agonist 
from the receptors, yet not activate the 
receptors as much as the full agonist 
had. The net effect would be a 
decrease in agonist effect and a
precipitated withdrawal syndrome. 
Precipitated withdrawal with a partial 
agonist is more likely to occur in an
individual who has a high level of
physical dependence (e.g., high use of
opioids each day), who takes the
partial agonist soon after a dose of full
agonist, and/or who takes a high dose 
of the partial agonist (CSAT, 2004). 
Affinity, Intrinsic Activity, and 
Dissociation 
The strength with which a drug binds
to its receptor is termed its “affinity.” 
The degree to which a drug activates 
its receptors is termed its “intrinsic 
activity.” Affinity for a receptor and 
activation of the receptor are two
different qualities of a drug. A drug 
can have high affinity for a receptor
but not activate the receptor (e.g., an
antagonist). Mu opioid agonists,
partial agonists, and antagonists can
vary in their affinity. In addition to
variation in affinity and intrinsic 
activity, drugs also vary in their rate 
of dissociation from receptors. 
“Dissociation” is a measure of the 
disengagement or uncoupling of the 
drug from the receptor. Dissociation is 
not the same as affinity—a drug can 
have high affinity for a receptor (it is
difficult to displace it from the
receptor with another drug once the
first drug is present), but it still
dissociates or uncouples from the 
receptor with some regularity. 
Buprenorphine’s slow dissociation 
contributes to its long duration of 
action (CSAT, 2004). 
Characteristics of Abused Drugs 
The rate of onset of the 
pharmacological effects of a drug, and 
thereby its abuse potential, is
determined by a number of factors.
Important among these are the drug’s 
route of administration, its half-life,
and its lipophilic property (which 
determines how fast the drug reaches 
the brain). A faster route of drug
administration (e.g., injection, 
smoking), a shorter half-life, and a 
faster onset of action are associated 
with a higher abuse potential of a 
drug. With all classes of drugs of
abuse, the likelihood of abuse is
related to the ease of administration, 
the cost of the drug, and how fast the 
user experiences the desired results
after the drug’s administration (CSAT, 
2004). 
11 
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Pharmacological Properties 
Buprenorphine is characterized 
pharmacologically as an opioid partial
agonist with both agonist and
antagonist properties, depending on 
dosage and clinical circumstances. It 
can be abused, particularly by
individuals who are not physically 
dependent upon opioids, but its
maximal effects are significantly less 
than those of full agonists such as
heroin and methadone (CSAT, 2004). 
At lower doses, buprenorphine acts as
an opioid agonist, enabling opioid-
dependent individuals to discontinue 
opioids without experiencing
withdrawal. At moderate doses, the 
agonist effects reach a plateau (ceiling
effect). At higher doses, the opioid
antagonist properties dominate and, 
in certain circumstances, higher doses 
of buprenorphine can displace opioid 
agonists, precipitating withdrawal 
symptoms in acutely opioid-
intoxicated individuals. 
(http://buprenorphine.samhsa.gov/
about.html). 
Buprenorphine’s ceiling effect
enhances its safety profile, making it 
less likely to produce opioid overdose 
and reducing its potential for 
diversion (National Association of
State Alcohol and Drug Abuse
Directors (NASADAD), 2002). The
combination of buprenorphine (a
partial agonist) and naloxone (a pure 
antagonist) in Suboxone® discourages 
patients dependent on mu opioid 
receptor agonists (heroin, methadone, 
hydrocodone, oxycodone, and the like)
from injecting dissolved tablets and
further decreases the likelihood of 
diversion and abuse. 
Buprenorphine is also a long-acting
agent, so many patients may not need 
to take medication every day. These 
properties may offer some treatment
advantages over the use of methadone. 
Monotherapy and 
Combination Therapy 
In October 2002, the FDA approved
two products for the treatment of
opioid dependence: 
1. 	 Subutex®: buprenorphine
monotherapy product; and 
2. 	 Suboxone®: buprenorphine and
naloxone combination product. 
Other forms of buprenorphine (e.g.,
Buprenex®) are NOT approved for
opioid addiction treatment. The 
Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of
Opioid Addiction, a consensus-based 
treatment guideline published by
SAMHSA, recommends that the 
buprenorphine and naloxone
(Suboxone®) combination product be 
used for most patients (CSAT, 2004).  
Dosing 
Subutex®, the buprenorphine-only
formulation, is available as sublingual
tablets in doses of 2 milligrams (mg) 
and 8 mg. Suboxone®, the
buprenorphine and naloxone
combination product, is available as
sublingual tablets in doses of 2 mg 
buprenorphine/0.5 mg naloxone, and 
8 mg buprenorphine/2 mg naloxone.
Naloxone is added to buprenorphine to
decrease the potential for abuse by the 
parenteral route. Usually dosage is
adjusted over several days. Initial 
prescriptions may be limited to 1-day
doses for the first several days before 
providing a prescription for several
days. Usually, 2–4 mg of buprenorphine
are administered sublingually on the 
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first day of treatment, then the patient 
is monitored for 2 hours. If signs or 
symptoms of withdrawal develop after
the first dose, another 2–4 mg may be
administered. Typically, the total dose 
on the first day should not exceed 8 mg. 
The FDA Web site at 
http://www.fda.gov/cder/drug/infopage/ 
subutex_suboxone contains drug-
labeling information for Subutex® and 
Suboxone®. If the patient continues to 
complain of withdrawal symptoms 
after receiving 8 mg of buprenorphine, 
symptoms may be managed with
nonopioid over-the-counter
medications. This phenomenon is not 
common, and most patients find that 
8 mg alleviates withdrawal symptoms.
The average maintenance dose is
usually 16 mg. Some patients may
need several days to stabilize on their
dose, and they may have some
discomfort for several days during the 
induction process. Although the 
treatment flow charts in appendix B
include a maximum daily
buprenorphine dose of 32 mg, more
recent clinical data suggest that daily 
doses above 24 mg do not provide 
additional therapeutic benefit to the 
vast majority of patients. Clinical 
trials underway could establish an 
even lower maximum daily
buprenorphine dose recommendation
(Greenwald et al., 2003). 
Abuse Potential 
Because of its opioid-agonist effects,
buprenorphine can be abused,
particularly by individuals who are 
not physically dependent on opioids.
However, the abuse potential is low in
comparison with that of full agonists. 
In the Suboxone® product, the opioid-
antagonist medication naloxone is 
combined with buprenorphine to 
decrease the likelihood that 
opioid-dependent patients will inject
the medication.  
Sublingual naloxone has relatively low
bioavailability, while sublingual
buprenorphine has good
bioavailability. Both naloxone and
buprenorphine have poor
gastrointestinal bioavailability. Thus, 
if a tablet containing both
buprenorphine and naloxone is taken
sublingually, as directed, the patient 
will experience predominantly a 
buprenorphine effect. However, if an
opioid-dependent person dissolves and
injects the combination tablet, the
antagonistic effect of naloxone will 
predominate because of the high
parenteral bioavailability, and opioid-
dependent patients will experience a
precipitated withdrawal syndrome. 
Thorough counseling of buprenorphine 
therapy candidates about the risk of 
precipitated withdrawal if they crush 
and inject the combination tablet
(Suboxone®) will decrease the 
likelihood of its misuse. 
Under certain circumstances, 
buprenorphine by itself may also
precipitate withdrawal in opioid-
dependent individuals. This
withdrawal is more likely to occur 
with higher levels of opioid 
dependence, with higher doses of
buprenorphine, or with shorter time 
intervals between the dose of an opioid 
full agonist and a dose of
buprenorphine (e.g., up to 6–8 hours
for short-acting opioids or more than 
24 hours for long-acting opioids). 
Safety Profile 
Because of buprenorphine’s ceiling
effect, the drug is less likely than 
opioid full agonists to produce
respiratory depression and other
adverse effects. The maximal agonist 
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effects of buprenorphine appear to 
occur in the dose range of 16–32 mg
for sublingual tablets (CSAT, 2004). 
However, according to FDA labeling 
(FDA, 2002), cases of cytolytic
hepatitis and hepatitis with jaundice 
have been observed in the population 
of persons who are addicted to opioids
and receiving buprenorphine, both in 
clinical trials and in postmarketing 
adverse event reports. The spectrum
of abnormalities ranges from transient 
asymptomatic elevations in hepatic
transaminases to case reports of
hepatic failure, hepatic necrosis,
hepatorenal syndrome, and hepatic 
encephalopathy. In many cases, the
presence of pre-existing liver enzyme
abnormalities, infection with hepatitis 
B virus (HBV) or hepatitis C virus
(HCV), concomitant usage of other 
potentially hepatotoxic drugs, and 
ongoing injecting drug use may have 
played a causative or contributory
role. In other cases, insufficient data 
were available to determine the 
etiology of the abnormality. The
possibility exists that buprenorphine
had a causative or contributory role in 
the development of the hepatic
abnormality in some cases. Liver 
function tests, measured prior to 
initiation of treatment, are 
recommended to establish a baseline. 
Periodic monitoring of liver function
tests during treatment is also 
recommended. A biological and 
etiological evaluation is recommended
when a hepatic event is suspected.
Depending on the case, the drug 
should be carefully discontinued to
prevent withdrawal symptoms and a 
return to illicit drug use; strict 
monitoring of the patient also should 
be initiated. 
Also, Suboxone® and Subutex® may
impair the mental or physical abilities 
required for the performance of
potentially dangerous tasks such as
driving a car or operating machinery, 
especially during drug treatment
induction and dose adjustment. 
Patients should be cautioned about 
operating hazardous machinery,
including automobiles, until they are 
reasonably certain that buprenorphine
therapy does not adversely affect their 
ability to engage in such activities.
Like other opioids, Suboxone® and 
Subutex® may produce orthostatic
hypotension in ambulatory patients
(adapted from FDA labeling for
Suboxone® and Subutex®, 2002, at
http://www.fda.gov/cder/foi/label/2002/
20732,20733lbl.pdf). 
Pregnancy 
Research on the safety and efficacy of
buprenorphine in pregnant women 
and neonates is scarce, and data on
the pharmacokinetics of
buprenorphine in pregnant women 
and neonates are extremely limited
(Johnson et al., 2003; Marquet et al.,
1997). The FDA classifies
buprenorphine as a Pregnancy 
Category C drug. The FDA Pregnancy
Labeling Task Force, whose long-term 
goal is to determine how animal 
toxicologic information contributes to
clinically meaningful information in
pregnancy, assigns a prescription drug 
for humans to Pregnancy Category C 
(1) if animal reproduction studies have 
shown an adverse effect on the fetus,
(2) if there are no adequate and well-
controlled studies in humans, and 
(3) if the benefits from the use of the 
drug in pregnant women may be
acceptable despite its potential risks. 
In addition to considering the FDA 
warnings pertaining to the use of 
buprenorphine in pregnant women, 
physicians and other health care
providers also must consider the risks 
14
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of infectious diseases and lifestyle 
issues (e.g., poor nutrition, lack of
prenatal care) when addressing the 
needs of these patients (CSAT, 2004).  
There is also a question whether the
buprenorphine and naloxone
combination is recommended for use 
in pregnancy. Naloxone is labeled by
FDA as a Pregnancy Category B drug. 
The FDA Pregnancy Task Force
assigns a prescription drug for
humans to Pregnancy Category B (1) if
animal reproduction studies failed to
demonstrate a risk to the fetus and 
(2) if there are no adequate and well-
controlled studies in pregnant women.
Despite the fact that naloxone is 
classified as Pregnancy Category B, it 
should be used with caution in 
pregnant women who are addicted to 
opioids. 
Because both mother and fetus will be 
dependent on the opioids used by the 
mother, administration of naloxone 
could precipitate withdrawal in both. 
If it is determined that buprenorphine 
is the only acceptable option for the
treatment of the pregnant woman, and
she understands the issues and risks, 
then she should be treated with
buprenorphine monotherapy so as to
avoid the risk of fetal exposure to 
naloxone. It should be noted that use 
of buprenorphine monotherapy,
because of its greater potential for
abuse, necessitates more frequent 
monitoring of patients and their
medications (e.g., every 1–2 weeks)
(CSAT, 2004). 
Adverse Effects 
The adverse effects of buprenorphine
are similar to those of other opioids,
but usually these effects are less
intense than those seen with full 
agonists. The most common adverse 
effects of buprenorphine are nausea, 
vomiting, headaches and constipation, 
which can be severe enough to make 
some patients not want to continue 
with induction. It can be difficult in 
the beginning to distinguish between 
ongoing, unresolved withdrawal from 
the abused opioid drug and
withdrawal that is precipitated by the 
buprenorphine. Please refer also to the 
section on Precipitated Withdrawal
and Withdrawal Symptoms. 
Interactions, Cautions, and 
Contraindications 
For a complete list of drug 
interactions, contraindications, 
warnings, and precautions, please
refer to the Subutex® and 
Suboxone® package inserts 
(http://www.suboxone.com/pdfs/
SuboxonePI.pdf). 
• In some instances, relapse to opioid 
drug use may be life threatening. A 
number of deaths have occurred 
when individuals have misused 
buprenorphine intravenously,
particularly when there is 
concomitant use of benzodiazepines, 
alcohol, or other opioids. Patients
should be warned of the potential
danger of self-administration of
benzodiazepines or other central 
nervous system depressants while 
under treatment with Subutex® or 
Suboxone®. 
• Patients should tell their family
members and friends that, in the 
case of emergency, the treating
physician or emergency room staff
should be informed that the patient 
is physically dependent on opioids 
and that the patient is being treated
with Subutex® or Suboxone®. 
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• In the case of overdose, primary
management should be the re­
establishment of adequate 
ventilation with mechanical 
assistance of respiration, if required. 
Naloxone may not be effective in
reversing respiratory depression
produced by buprenorphine. 
• Patients with hepatic (liver) disease
may not properly metabolize these
drugs; their doses may need to be
adjusted, and these patients should 
be observed for opioid toxicity or
precipitated opioid withdrawal. 
• Drugs that require extra precautions 
and may require dosage adjustments
include ketoconazole, an antifungal
medication frequently used with
patients with HIV/AIDS; certain 
antibiotics; HIV protease inhibitors
and non-nucleoside reverse 
transcriptase inhibitors; and certain
barbiturates used to control epilepsy
(seizures). 
• Buprenorphine products should be 
administered with caution in elderly 
or debilitated individuals, and in 
those with severe impairments in
hepatic, pulmonary, or renal
function. 
Allergic Reactions 
Cases of acute and chronic 
hypersensitivity to buprenorphine 
have been reported both in clinical 
trials and in the postmarketing 
experience. The most common signs
and symptoms include rashes, hives, 
and pruritus. Cases of bronchospasm, 
angioneurotic edema, and 
anaphylactic shock have been 
reported. A history of hypersensitivity 
to buprenorphine is a contraindication 
to Subutex® or Suboxone® use. A 
history of hypersensitivity to naloxone 
is a contraindication to Suboxone® use. 
(Adapted from FDA labeling for 
Suboxone® and Subutex®, 2002, at
http://www.fda.gov/cder/foi/label/2002/ 
20732,20733lbl.pdf.)
Several medical conditions and 
medications, as well as concurrent 
abuse of other drugs and alcohol,
necessitate caution or are relative 
contraindications to buprenorphine 
treatment. Examples include (CSAT, 
2004): 
• Seizures. Caution should be taken 
when buprenorphine is used
concurrently with antiseizure
medications (e.g., carbamazepine). 
In addition, the relative risk of 
interaction between buprenorphine 
and sedative hypnotics (e.g., 
phenobarbital) should be kept in
mind. Monitoring for therapeutic 
plasma levels of antiseizure
medications should be considered. 
• HIV. Caution should be taken when 
buprenorphine is used in
combination with HIV antiretroviral 
medications, because they may 
inhibit, induce, or be metabolized by 
the cytochrome P450 3A4 enzyme
system. These patients may require 
dosage adjustment. 
• Hepatitis and impaired hepatic
function. Viral hepatitis, such as
infection with HBV and HCV, is
common among individuals who 
abuse opioids and should be
evaluated and treated appropriately. 
Although pharmacotherapy with
buprenorphine is not
contraindicated on the basis of
mildly elevated liver enzymes, liver
enzymes should be evaluated prior 
to induction of treatment and 
monitored frequently; dosage
modifications may be necessary.  
• Pregnancy. Risks and benefits of
buprenorphine treatment must be 
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considered if the patient is pregnant
or likely to become pregnant during 
the course of treatment with 
buprenorphine. Detoxification
should not be considered for women 
who become pregnant while on 
buprenorphine products; this could 
be harmful to the fetus. If these
women continue with buprenorphine 
therapy (as opposed to switching to 
methadone), they should be switched 
from Suboxone® to Subutex®. 
• Use of other drugs.
Buprenorphine is a treatment for
opioid addiction, not for addiction to 
other classes of drugs. Patients who
use or abuse more than one 
substance present unique problems 
and may need referral to resources 
outside the office setting for more 
intensive treatment. 
• Alcohol. Since alcohol is a sedative-
hypnotic drug, patients should be 
advised to abstain from alcohol 
while taking buprenorphine.
Patients may present with
withdrawal symptoms from other 
drugs at the same time they are 
experiencing opioid withdrawal 
symptoms. Buprenorphine will not
control seizures caused by 
withdrawal from alcohol or other 
sedative-hypnotic substances.  
Cost and Supply 
Prescriptions written by qualified 
physicians will be valid at any 
pharmacy, but not all pharmacies 
carry these medications. If qualified 
physicians treat patients with
buprenorphine products but do not 
maintain supplies of tablets for 
induction, they must establish
relationships with one or more specific 
pharmacies that can provide initial 
doses and provide specific instructions 
for patients to return to the office 
setting for induction and follow-up
prescriptions. Prescribers of 
buprenorphine are responsible for
familiarizing themselves with all
pertinent Federal regulations as well
as State-specific requirements for the
maintenance of buprenorphine 
products in office settings.  
For more information about State-
specific requirements for maintenance 
of buprenorphine products in office 
settings, or for instructions on 
establishing relationships with
suppliers of the medication for 
induction use, refer to the Suboxone® 
Web site (http://www.suboxone.com) or
call 1–877–SUBOXONE. 
The cost of therapy may be a major
limitation to the use of buprenorphine 
products (Suboxone® and Subutex®).
Nurses who work with opioid-
dependent individuals should become
familiar with State and local resources 
and funding requirements for
reimbursement through both public 
and private payers. State substance
abuse treatment directors may provide 
more information about specific State
and local resources to fund 
buprenorphine therapy. Refer to the
National Association of State 
Alcohol/Drug Abuse Directors
(NASADAD) Web site at
http://www.nasadad.org/index.php?
base_id=283 for information about 
how to contact substance abuse 
directors in particular States.  
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Buprenorphine Treatment 
Protocols—Office-Based Treatment 
Office-based treatment of opioid
dependence, in contrast to federally 
regulated opioid treatment programs 
(OTPs), is now permitted by DATA 
2000. Office-based treatment involves 
the coordination of services by a
physician’s office as opposed to OTPs 
in which physicians have limited
involvement (Fiellin & O’Connor,
2002). 
Advantages and challenges are 
associated with providing office-based
treatment. The advantages include
(1) increasing  the availability of 
treatment, (2) the ability to tailor 
services  to the needs of patients, 
(3) minimization of the potential 
stigma  associated with treatment, and 
(4) limiting patients’ contact with 
drug-abusing patients. 
Challenges to implementing office-
based treatment include (1) the need 
for health care providers to acquire 
clinical experience with a new 
population of patients who abuse or 
are addicted to opioids and other 
drugs, and (2) the ability to provide or 
recommend appropriate psychosocial 
services (such as counseling, 
educational, and vocational services). 
In addition, issues such as
inappropriate prescribing, medication 
diversion, and patient confidentiality
must be addressed properly (CSAT,
2004; Fiellin &and O’Connor, 2002). It
is vital for nurses to seek educational 
courses (such as buprenorphine 
courses offered by the ASAM) to 
improve their professional skills and 
prepare them for best practices in the 
addiction settings. For more
information on buprenorphine 
treatment training please visit the
following Web site:
http://buprenorphine.samhsa.gov/pls/
bwns/training.html. 
Medically Supervised 
Withdrawal (Opioid 
Detoxification With 
Buprenorphine) 
The term “medical withdrawal” has 
been chosen by experts in the field
because it more accurately reflects the
physician’s role in withdrawal.
(adapted from CSAT Guidelines for
the Accreditation of Opioid Treatment 
Programs 1999 at 
http://www.dpt.samhsa.gov/pdf/
guidelines.pdf).
For patients who are physically 
dependent on heroin or other short-
acting opioids, buprenorphine may be 
initiated at least 6–8 hours, but
preferably 12–24 hours, after the 
patient last used opioids (CSAT, 
2004). Optimally, buprenorphine
should be administered when the 
patient exhibits definite signs of 
withdrawal. The maximal 
recommended induction dose of
buprenorphine is 8 mg on day 1 (given
at once or in divided doses, as 
clinically indicated) (CSAT, 2004). 
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Precipitated withdrawal may occur in 
switching from methadone or other 
long-acting medication to 
buprenorphine. Therefore, patients
who are physically dependent on
methadone or other long-acting
opioids must be carefully selected for 
buprenorphine therapy. Appropriate
patients may include those who have
had difficulty adhering to scheduled 
visits at OTPs due to personal 
conflicts and work schedules or travel, 
as opposed to those who have been
noncompliant with methadone
treatment appointments. Other
appropriate candidates include
patients who have a history of
uncontrollable adverse effects or true 
hypersensitivity to methadone. 
Patients who are stable on methadone 
maintenance and who do not have a 
compelling reason to switch therapy 
should continue methadone 
maintenance because of the elevated 
risk for precipitated withdrawal 
during the conversion from methadone
to buprenorphine. This risk is
especially significant when
buprenorphine is started shortly after 
the last methadone dose, and in
patients maintained on methadone
doses greater than 30–40 mg daily. To
avoid precipitous onset of withdrawal
symptoms, long-acting opioids should
be tapered to the equivalent of 30–40
mg of methadone daily, and the last 
dose of methadone should be taken at 
least 24 hours prior to initiation of the
buprenorphine therapy for methadone
and at least 48 hours for levomethadyl
acetate (LAAM). Note that this 
conversion dose of methadone should 
not be considered as the dose 
equivalent to a starting dose of 
buprenorphine. The induction dose of
buprenorphine should start at 2 mg
and may be repeated, as needed, up to 
8 mg in a 24-hour period (CSAT,
2004). 
Medically supervised withdrawal is 
only the first stage of addiction
treatment and by itself often does
little to change long-term drug use. 
The goal of medically supervised
withdrawal is to manage the acute 
physical symptoms of withdrawal 
safely. Medically supervised 
withdrawal is strongly indicated as a 
precursor to effective drug-addiction
treatment for some individuals. 
However, medically supervised
withdrawal alone is rarely sufficient to 
achieve long-term abstinence (CSAT,
2004; CSAT, 2005a). Providers must
help patients avoid withdrawal 
symptoms while making a smooth 
transition from a physically dependent
to a physically nondependent state, so
patients can then engage in further 
rehabilitation to prevent relapse 
without opioid-agonist treatment. To 
be effective, medically supervised 
withdrawal should be followed by
long-term drug treatment therapy or
naltrexone therapy to minimize the 
risk of relapse to opioid abuse (CSAT 
2004). 
[A]bsent a compelling need for 
the complete avoidance of all
opioids, long-term maintenance 
treatment with buprenorphine is 
to be preferred in most instances 
to any form of detoxification or
withdrawal treatment. The 
literature suggests that the use of
buprenorphine for gradual
detoxification over long periods is
probably more effective than its
use for rapid medically 
supervised withdrawal over short 
or moderate periods (CSAT, 2004,
page 59). 
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The optimal rate at which
buprenorphine should be reduced is a
matter of ongoing research. However, 
the dose may be decreased by as much
as 50 percent per day, with a mild 
withdrawal syndrome that generally 
becomes manifest several days after 
the last dose and that can be treated 
with non-opioid, over-the-counter
symptomatic remedies.  
The best method is one that is slow,
easy, and comfortable for patients. 
Medical withdrawal of compliant 
patients should proceed slowly at a
rate that the prescriber determines to 
be therapeutic (for example, at 2 mg 
per month until the patient feels ready 
to discontinue buprenorphine 
altogether). 
Noncompliant patients may need to be 
transferred to other medical 
treatment, such as methadone
programs, or to nonmedical treatment 
programs where they can receive more 
structure and supervision.  
Classifications of Medically 
Supervised Withdrawal 
• Short-term medically supervised 
withdrawal. Patients with a 
compelling reason to be opioid-free 
quickly (impending incarceration, 
foreign travel, job requirement, etc.) 
will be considered for this method, in 
which the buprenorphine dose is
reduced over 3 days or longer and 
then discontinued. This method is 
better accepted and more effective in 
relieving withdrawal symptoms than 
is clonidine (Cheskin, Fudala, & 
Johnson, 1994). However, data are 
insufficient about relapse rates and 
long-term outcomes for patients who
undergo short-term withdrawal 
(CSAT, 2004). 
• Mid-term medically supervised 
withdrawal. Patients without a 
compelling need to undergo short-
term medically supervised 
withdrawal, but with a desire to be 
opioid free and to engage in
rehabilitation, may be placed in a 
moderate-period reduction. Patients
in this group may be withdrawn
over a period of 10–14 days or more
(up to 30 days) (CSAT, 2004). 
• Long-term medically supervised 
withdrawal. Patients who are 
unwilling or unable to engage
actively in rehabilitation services
without agonist support may not be 
good candidates for short-term
detoxification, but they may benefit 
from a long period of reduction, 
which may last between 30 and
180 days. These patients may also
be suitable candidates for 
maintenance therapy (CSAT, 2004).  
Few patients are likely to maintain 
abstinence without medication, so
medically supervised withdrawal is 
considered only for patients with
evidence of sustained medical and 
psychosocial stability. Patients should
be encouraged to continue with
buprenorphine maintenance therapy if
medically supervised withdrawal is 
unsuccessful. 
Maintenance Treatment 
The three phases of buprenorphine 
therapy include induction, 
stabilization, and maintenance. 
Maintenance is reached when the 
patient is doing well on a steady dose
of buprenorphine—preferably
Suboxone®, the buprenorphine and 
naloxone combination product. 
• Induction phase. The induction 
phase is the medically monitored 
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and supervised start-up of 
buprenorphine therapy. The goal of 
induction is to find the minimum 
dose at which the patient markedly 
reduces or eliminates use of other 
opioids and experiences no 
withdrawal symptoms, side effects, 
or cravings. Induction can be 
initiated in the physician’s office, 
with induction doses administered 
as observed treatment, and 
subsequent doses provided through 
prescription (CSAT, 2004). Most 
patients can be inducted into 
treatment over 2–3 days by using 
the combination product Suboxone®. 
During the induction phase, 
buprenorphine products are 
administered when an opioid-
dependent individual has abstained 
from using short-acting opioids for 
at least 6–8 hours, and when 
individuals on long-acting opioids 
have abstained for more than 
24 hours and are in the early stages 
of withdrawal. Buprenorphine 
treatment cannot begin until 
patients are exhibiting objective 
signs and symptoms of opioid 
withdrawal. If patients are not in 
the early stages of withdrawal (i.e., 
when they have other opioids in the 
bloodstream), the administration of 
buprenorphine may precipitate 
withdrawal (FDA, 2002; HRSA-
BPHC, 2003).  
Patient education is very important 
in the induction phase. Withdrawal 
involves extreme discomfort, and 
patients may act to avoid it. It may 
be particularly helpful to ask 
patients about their typical first 
three signs of withdrawal and when 
they occur, so that the patient and 
provider can work together to 
prevent withdrawal.  
One exception to the rule about 
adequate objective withdrawal signs 
is the highly motivated patient who 
has already detoxified himself 
several days before beginning 
induction. This patient may not 
exhibit significant objective 
withdrawal symptoms but may be 
dealing with significant cravings 
(Kathleen Thompson-Gargano, 
personal communication, October 
2006). 
• Stabilization phase. The 
stabilization phase begins when 
patients who have discontinued or 
greatly reduced the use of their drug 
of abuse no longer have cravings and 
are experiencing few or no side 
effects. The buprenorphine dose may 
need to be adjusted during this 
phase. Once stabilization has been 
achieved, the long half-life of 
buprenorphine sometimes makes it 
possible to switch patients to 
alternate-day dosing (HRSA-BPHC, 
2003). Psychosocial counseling is a 
priority during the stabilization 
phase (HRSA-BPHC, 2003).  
• Maintenance phase. The 
maintenance phase is reached when 
the patient is doing well on a steady 
dose of buprenorphine (preferably 
Suboxone®, the buprenorphine and 
naloxone combination product). The 
length of time of maintenance 
therapy is individualized, and it may 
be indefinite (CSAT, 2004). Patients 
should receive ongoing assessments 
and urine drug screens (CSAT, 
2004).  
 
Initially, patients should be seen 
daily or have daily phone contact 
while induction is being completed. 
Then they should be seen at least 
weekly until they are well stabilized, 
when they may be seen no less 
frequently than every 4 weeks 
(CSAT, 2004).  
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Physicians should determine the
length of treatment on buprenorphine
according to the individual patient’s
needs and be sure to involve patients 
in the development of their treatment 
plans. The length of treatment may be 
as short as a few days for medical
withdrawal (detoxification) services to
as long as several years for
maintenance therapy. 
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Precipitated Withdrawal and 
Withdrawal Symptoms 
Avoiding Precipitated 
Withdrawal 
Precipitated withdrawal is more likely to
occur with higher levels of opioid
dependence, with short-time intervals 
(e.g., less than 2 hours) between a dose of
a full opioid agonist and a dose of
buprenorphine, and with higher doses of
buprenorphine. Withdrawal may be 
intense and of rapid onset. The best way
to avoid precipitated withdrawal is to 
assess accurately the individual’s
patterns of opioid use, to determine 
whether the patient was on short- or long-
acting opioid medications before initiating 
buprenorphine, and to monitor trial
dosing (http://www.pbm.va.gov/
criteria/BuprenorphineCriteriaForUse
.pdf; CSAT, 2004). 
Buprenorphine can precipitate an opioid
withdrawal syndrome if administered to
a patient who is opioid dependent and 
whose receptors are currently occupied 
by opioids. Therefore, a patient should
no longer have any residual opioid effect 
from his or her last dose of opioid before 
receiving a first dose of buprenorphine. 
This condition is of particular 
importance for patients on long-acting 
opioid agonists (e.g., methadone). Due to
this required abstinence before the
initiation of buprenorphine treatment,
it is likely that patients will feel that 
they are experiencing the early stages of
withdrawal when they present for 
buprenorphine induction treatment. If a
patient has early symptoms of 
withdrawal, the opioid receptors are 
unlikely to be occupied fully; 
precipitated withdrawal from 
administration of buprenorphine will be
avoided, and the efficiency of
buprenorphine in alleviating
withdrawal symptoms can be assessed 
more easily (CSAT, 2004). 
Assessment of Withdrawal 
Symptoms 
Common signs and symptoms of opioid 
withdrawal include: 
(http://buprenorphine.samhsa.gov/
about.html) 
Objective Subjective 
• Elevated pulse and blood pressure 
• Vomiting/diarrhea 
• Diaphoresis (sweating)
• Lacrimation (tears)
• Rhinorrhea (runny nose) 
• Dilated pupils 
• Piloerection (“goose flesh”) 
• Yawning 
• Mild fever 
• Dysphoric mood 
• Nausea  
• Muscle aches/cramps/bone pain  
• Low back pain 
• Abdominal pain 
• Insomnia 
• Craving 
• Anxiety/irritability/restlessness 
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Figure 1. Staging and Grading Systems of Opioid Withdrawal 

Early Withdrawal 
(8–24 hours after last use) 
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Stage Grade Physical Signs and Symptoms 
Early Withdrawal 
(8–24 hours after last use)
1 Lacrimation 
Rhinorrhea 
Diaphoresis
Yawning 
Restlessness
Insomnia 
2 Piloerection
Muscle twitching 
Myalgia 
Arthralgia 
Abdominal pain 
Fully Developed Withdrawal 
(1–3 days after last use) 
3 Tachycardia
Hypertension 
Tachypnea 
Fever 
Anorexia 
Nausea 
Extreme restlessness 
Fully Developed Withdrawal 
(1–3 days after last use) 
4 Diarrhea 
Vomiting 
Dehydration 
Hyperglycemia 
Hypotension
Curled-up position 
HIV Web Study (http://www.HIVwebstudy.org) Supported by HRSA 
As individuals progress through the 
following stages of opioid withdrawal, 
they progressively have more severe 
symptoms: (CSAT, 2004) 
Signs and symptoms of withdrawal
may be assessed by using
standardized instruments such as the 
Clinical Opiate Withdrawal Scale
(COWS) (Wesson & Ling, 2003), the
Subjective Opiate Withdrawal Scale
(SOWS) (Handelsman et al., 1987), or
the Objective Opiate Withdrawal 
Scale (OOWS) (Handelsman et al., 
1987) (see Appendix D: Assessment 
Instruments). 
Helping Patients Manage 
Mild Withdrawal Symptoms 
Usually, medically supervised
withdrawal from Suboxone® causes 
mild, transitory withdrawal 
symptoms. Patients should be
prepared for the occurrence of possible
symptoms such as reduced energy, 
reduced appetite, irritability, or
insomnia. It is also important for 
patients to understand that they can 
halt the medical withdrawal at any 
time and return to a higher dose. (See
Suboxone® Treatment Walkthrough:
http://www.suboxone.com/hcp/
opioiddependence/ 
suboxone_treatment.aspx.) 
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Tapering 
The patient’s Suboxone® dose should be 
tapered slowly at a rate that both the 
prescriber and the patient consider 
acceptable. Patients commonly want to 
taper more quickly, so helping patients 
set realistic goals at the outset is 
important. Some patients will ask to 
proceed directly from stabilization to 
medically supervised withdrawal. 
However, unless there is a compelling 
reason to discontinue Suboxone® 
quickly (e.g., travel), a slow taper is 
usually encouraged, because it is 
associated with a higher likelihood of 
treatment success (CSAT, 2004). 
Although no standard dosing protocol 
exists for medically supervised 
withdrawal, sample protocols are 
provided in the Suboxone® and 
Subutex® Dosing Guide at 
http://www.suboxone.com/hcp/ 
opioiddependence/ dosing_guide.aspx. 
Self-Management of Mild 
Withdrawal Symptoms With 
Over-the-Counter or 
Prescription Medications 
Medical withdrawal from Suboxone® 
causes mild withdrawal symptoms, such 
as muscle pain, nausea, gastrointestinal 
(GI) distress, and insomnia. Patients 
may benefit from over-the-counter 
medications or prescribed medications 
to alleviate symptoms.  
Over-the-counter medications for symptom 
relief include those listed in Erickson 
(2006) and at http://www.fda.gov/ 
cder/Offices/OTC/default.htm. 
• Ibuprofen, 800 mg by mouth every 
6 hours as needed for muscle aches  
• Acetaminophen, 1,000 mg by mouth 
every 4 hours as needed for pain  
• Maalox®, 30 cc by mouth every 
2 hours as needed for GI distress 
• Diphenhydramine, 50 mg by mouth at 
bedtime as needed for severe insomnia 
The following prescribed medications 
may be helpful at controlling 
withdrawal symptoms (see Erickson, 
2006; and http://www.fda.gov/ohrms/ 
dockets/dailys/03/jul03/072503/072503
.htm and http://www.fda.gov/cder/ 
Offices/OTC/default.htm). 
• Dicyclomine, 40mg by mouth every 
6 hours as needed for abdominal pain 
• Promethazine, 25 mg intra-
muscularly every 6 hours as needed 
for nausea and vomiting  
• Promethazine, 25 mg by mouth 
every 6 hours as needed for nausea  
• Lopermide, 2 mg by mouth every 
6 hours as needed for diarrhea  
• Clonidine, 0.1 mg by mouth every 
2 hours as needed for severe anxiety 
Management of Patients 
With Co-Occurring Pain 
Pain is an unpleasant sensory and 
emotional experience associated with 
actual or potential tissue damage, or 
described in terms of such damage 
(Merskey, 1979). Pain may be classified 
as either acute or chronic. Acute pain is 
associated with injury to body tissue, 
often accompanied with objective signs 
of sympathetic nervous system activity, 
and generally subsides as the injury 
heals. Chronic pain extends beyond a 
normal healing period, or in some cases 
the underlying cause of the pain cannot 
be identified. Chronic pain usually 
persists longer than 3 months and is 
rarely accompanied by symptomatic 
nervous system activity. Lack of 
objective signs may prompt the clinician 
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to conclude that the patient doesn’t 
appear to be in pain (APS, 2003; Loeser 
& Melzack, 1999). Both acute and 
chronic pain can have an impact on the 
dimensions of the patient’s quality of 
life including physical, social, 
psychological, and spiritual well-being 
(Ferrell et al., 1999).  
Pain Assessment 
The purpose of pain assessment is to 
(1) identify the pain level at which pain 
does not interfere with activities related 
to recovery or quality of life (QOL) level 
at which the patient can perform 
activities of daily living (ADLs); and 
(2) effectively measure interventions 
used in each patient’s pain management 
plan (Grimes, 2006). The criteria of pain 
assessment are as follows: 
Onset and 
treatment 
pattern 
• When did the pain start? 
• How often does the pain 
occur? 
• Has pain intensity 
changed? 
Location • Where is the pain? 
• Is there more than one 
site of pain? 
Description • What does the pain feel 
like? 
• What words describe the 
pain?  
Aggravating 
and 
alleviating 
factors 
• What makes the pain 
better? Worse? 
Previous 
treatment  
• What treatment have 
you tried to relieve the 
pain? 
• Were these effective? 
Effect • How does the pain affect 
physical and social 
function? 
Intensity • Using a pain scale, rate 
the intensity of the pain. 
(AHCPR, 1994) 
Multimodal Approach to the 
Treatment of Pain 
The first approach to the treatment of 
pain is pharmacologic intervention. 
Carr and Goudas (1999) state that 
patients with moderate to severe acute 
pain often require opioid analgesics 
while they are receiving regular 
opioid-agonist therapy. If acute pain 
remains undertreated, it will decrease 
a patient’s responsiveness to opioid 
analgesics; thus, controlling the 
subsequent pain will be far more 
difficult (Collett, 1998; Mao, Price, & 
Mayer, 1995). Multimodal analgesia, 
such as nonsteroidal anti-
inflammatory drugs (NSAIDs), and 
acetaminophen and adjuvant 
analgesics, such as tricyclic 
antidepressants that enhance opioid 
effects, may be an appropriate pain 
therapy to decrease the total amount 
of opioid provided to patients (Kehlet 
& Dahl, 1993; Mitra & Sinatra, 2004). 
Meanwhile, clinicians must continue 
the opioid-agonist treatment for the 
patient before prescribing analgesia to 
avoid the increased pain sensitivity 
associated with opioid withdrawal 
(Jasinski, 1997). 
The second approach is 
nonpharmacological interventions 
including physical and cognitive 
behavioral modalities. Cutaneous 
(skin) stimulation, exercise, 
immobilization, and acupuncture are 
examples of physical intervention. 
Cognitive behavioral modalities 
include relaxation and imagery, 
distraction and reframing, patient 
education, structured support, 
hypnosis, and pastoral counseling 
(Simon et al., 2002).  
Finally, ongoing assessment and 
documentation of pain management 
intervention are crucial. Nurses 
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should periodically assess the four 
“A’s” of pain management. Those 
include (1) Analgesia, (2) Activities of 
daily living, (3) Adverse effects, and 
(4) Aberrant drug-related behaviors
(APS, 2003). 
Management of Acute Pain in 
Patients on Buprenorphine 
Maintenance Therapy 
If the patient requires opioid
analgesics while receiving 
buprenorphine maintenance therapy,
the following options may be 
appropriate (Alford, Compton, &
Samet, 2006): 
1. Provide titrated short-acting opioid
analgesics (for short-duration pain 
only) while continuing

buprenorphine maintenance

therapy. 

2. Administer opioid analgesics while 
discontinuing buprenorphine 
maintenance therapy. Return to
buprenorphine therapy when acute 
pain is less intense and does not 
require opioid analgesics.
3. Divide buprenorphine dose, and
administer every 6–8 hours.
4. Discontinue buprenorphine in case of 
hospitalization, and provide
methadone (20–40 mg) for treating
opioid dependence and short-acting
opioid analgesics for treating pain.
Availability of naloxone as an opioid 
antagonist in this situation is also 
necessary in case of emergency. 
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Physicians’ and Patients’ 

Responsibilities 

To improve outcomes of pharmacologic 
therapies provided in office-based
settings, practitioners must be clear
about their treatment philosophy, 
expectations, and office rules. They 
must manage medication accurately 
during all stages of treatment.
Providers should inform patients of
clinic procedures and protocols, hours
of operation, phone numbers, 
procedures for making appointments, 
fees, proper medication administration 
and storage, side effects and
precautions, rights and 
responsibilities, and other practice-
specific protocols or guidelines. In
many States, physicians can
periodically check Prescription
Monitoring Programs (PMPs). 
The following “red flag” behaviors 
should be addressed with patients 
immediately, and nurses should
support patients in making
appropriate responses to them 
(OMIROR, 2003): 
• Missing appointments 
• Refusing urine testing or 
breathalyzer 
• Running out of medications too soon 
• Taking medications off schedule
• Not responding to phone calls 
• Neglecting to mention new
medication or outside treatment 
• Appearing intoxicated or disheveled 
in person or sounding intoxicated on 
the phone 
• Making frequent, urgent, or
inappropriate phone calls 
• Neglecting to mention change in 
address, job, or home situation 
• Having inappropriate outbursts of 
anger 
• Reporting lost or stolen medication 
• Having frequent physical injuries or
auto accidents 
• Not paying bills 
Other warning signs include: (LaBelle, 
2006) 
• Drug screens positive for opioids or 
illicit drugs 
• Request for higher doses after 
stabilization 
• Evidence of tampering with drug
tests 
• Drug screens negative for
buprenorphine (point of collection
tests are available) 
• Changes in behavior
• No engagement in counseling or self 
help 
• Depression, withdrawal, or social 
isolation 
• Weight loss 
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Information about patient
responsibilities should be clearly
articulated in a “treatment contract” 
that should be signed by both the
patient and the physician. At a
minimum, the treatment contract 
should cover components discussed 
below: (McCance-Katz, 2004;
OMIROR, 2003) 
• Voluntary participation. Patients 
should freely and voluntarily agree 
to receive buprenorphine products 
for the treatment of opioid addiction, 
provided that they accept the
conditions of the treatment contract. 
• Pregnancy. Women of childbearing 
age should receive a pregnancy test
(urine human chorionic
gonadotropin (HCG) test) before
treatment is initiated and monthly
or intermittently thereafter. Female
patients should tell the physician if 
they are pregnant, plan to become 
pregnant, or are breastfeeding. It is 
not known whether Subutex® or 
Suboxone® may harm unborn
children or infants. 
• Use of other medications.
Patients should agree not to obtain
medications (prescription or
nonprescription, including vitamins
and herbal supplements) from 
physicians, pharmacists, or any 
other source without the approval of
the physician who provides the
buprenorphine therapy. Mixing
buprenorphine with other
medications—especially 
benzodiazepines such as diazepam 
(Valium), clonazepam (Klonopin),
lorazepam (Ativan),
chlordiazepoxide (Librium),
alprazolam (Xanax), midazolam
(Versed), and other drugs of abuse—
may be particularly dangerous and
may cause death. 
• Use of alcohol and other illicit 
drugs. Because alcohol is a 
sedative-hypnotic drug, its use is 
strongly contraindicated, and 
patients should be advised to
abstain from alcohol while taking 
buprenorphine (CSAT, 2004).
Furthermore, patients should be
warned that the use of cocaine or 
other illicit drugs is contraindicated,
because such use often leads to 
relapse. 
• Use of medications only as
prescribed. Patients should take 
their medications on time and 
should not adjust their dose on their 
own. If patients desire a dose
change, they should call for an
appointment to discuss this with 
their physician. 
• Scheduled appointments.
Patients should agree to keep and 
arrive on time for all scheduled 
appointments while taking 
buprenorphine products. Missed 
appointments may result in not 
being able to get medication until
the next scheduled visit. 
• Compliance with required pill 
counts and drug tests. Drug
testing is a mandatory part of office
maintenance. The physician should 
consider ordering drug testing (e.g., 
urine samples) and pill counts at
each visit. 
• Counseling and other referrals.
Patients must agree to keep
appointments for any recommended 
psychosocial counseling (including
12-step or other self-help programs)
and to accept referrals for other 
ancillary services as mutually
agreed upon by the prescriber,
nurse/counselor, and the patient. 
• Under the influence. Patients are 
instructed not to come to the 
program intoxicated or under the 
influence of alcohol or drugs,
because it is very unsafe to do so. If 
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they do come to the program 
intoxicated or under the influence,
they will not be medicated and may 
be discharged from buprenorphine 
treatment. However, patients who
admit to drug use are asking for 
help and should be congratulated 
and acknowledged for this openness, 
because it is behavior conducive to 
recovery and health maintenance. 
• Recovery and relapse. Relapse to
opioid drug use can be life 
threatening, and the treatment plan
should be adjusted accordingly. 
Trust should be established with the 
patient so that the patient may be
more willing to notify the physician
about a relapse before it is detected
with a drug test. The physician and
nurse should adopt a matter-of-fact 
and nonpunitive approach with the
patient in response to relapse.  
• Diversion. Patients must agree not 
to sell, share, or give any medication 
to other persons. Such mishandling 
is a serious violation that may result
in discharge. Patients should notify
the physician immediately in case of 
lost or stolen medication. If a police
report is filed, the patient should 
bring in a copy for the record. 
• Safe storage. Medication may be 
harmful to children, household
members, guests, and pets. Patients 
should be instructed to store the
medication in a safe place and to
keep the medication in child safety 
containers, out of the reach of
children. They should call the poison 
control center or 911 if anyone other
than the patient ingests the
medication. Lost medication will not 
be replaced. Medication should not 
be kept in places of temperature 
extremes such as a glove
compartment, or in a bathroom 
medicine chest where it can become 
moist or be taken by others.  
• Other safety issues. Patients 
should not drive, operate heavy
machinery, or perform other 
dangerous activities until they know 
how the medication affects them. 
Dangerous or inappropriate
behavior that is disruptive to the 
clinic and others will not be 
tolerated and may result in 
discharge from treatment. 
Nurses’ Responsibilities 
In OTPs, nonphysician health care
professionals such as nurses, nurse 
case managers, and NPs are permitted 
to conduct various activities under 
SAMHSA regulations. For example,
under 42 CFR 8.12(f), an authorized 
health care professional under the 
supervision of the program physician 
may conduct the required initial
physical examination. On the other 
hand, only a medical director or
program physician shall determine a
patient’s eligibility for take-home
medications under 42 CFR 8.12(i)(2) 
(http://www.dpt.samhsa.gov/
regulations/legreg.aspx). 
In office-based settings, nonphysician 
health care professionals such as 
nurses, nurse case managers, and NPs 
may be permitted to conduct physical 
examinations and other procedures. 
These procedures should be conducted 
under the supervision of the physician 
and documented in the job description, 
if they are permissible under the 
Nurse Practice Act in the State in 
which the nurse practices. However, 
the physician must determine the 
patient’s dosage of buprenorphine 
medication and the amount of 
medication permitted for take-home 
medication or the amount of 
medication to be dispensed with a 
prescription. 
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Nursing Practice and the Use of 
Buprenorphine for the Treatment of 
Opioid Addiction 

Screening and Assessment 
Nurses have a great role in screening 
and assessing the health status of
patients who have addiction problems. 
As a basic intervention, nurses can
identify problems caused by drug use 
(Clancy, Coyne & Wright, 1997).
Screening and assessment tools may
be used to help nurses identify
significant uncovered risks and
problems with drug and alcohol use
(Clancy, Coyne, & Wright, 1997). 
Initial screening. Initial screening 
should consist of a combination of 
objective screening instruments,
laboratory evaluations, and 
interview(s). If the buprenorphine 
prescriber suspects an addiction 
problem after reviewing the initial
results, further assessment is 
indicated. Indepth interviews and 
standardized assessments are the 
most effective means of gathering 
further information. Several validated 
addiction screening instruments are
available, such as the Drug Abuse
Screening Test (DAST-10) (see
Appendix C: Screening Instruments). 
Screening for individuals at risk 
for undetectable health and 
mental health disorders. Nurses 
can assist in ruling out co-occurring
disorders and can identify patients 
with comorbid conditions during their 
ongoing screening, assessment,
monitoring, and recovery 
management. 
Nurses may assist in: 
• Ruling out comorbid acute or chronic 
pain disorders and opioid 
dependence. 
• Ruling out polysubstance use—consider
using the Readiness Ruler (see 
Appendix C: Screening Instruments).  
• Ruling out co-occurring psychiatric 
disorders—consider using Mental 
Health Screening Form III (MHSF­
III) (see Appendix D: Assessment 
Instruments). 
• Questioning about potential 
pregnancy and child-bearing status. 
• Screening for infectious diseases
(hepatitis viruses, HIV, tuberculosis 
(TB), sexually transmitted diseases 
(STDs)). 
• Screening out domestic violence or
abuse. Please visit the following Web 
sites for more information on the 
domestic violence screening tools:
American Council of Obstetricians 
and Gynecologists,
http://www.acog.org/departments/
dept_notice.cfm?recno=17&bulletin=
585; and Domestic Violence: What 
Clinicians Should Know (2004),
http://www.ispub.com/ostia/index.php?
xmlFilePath=journals/ijapa/vol4n1/
violence.xml. 
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• Assessment. If screening tests 
indicate the presence of an opioid 
use disorder, further assessment is 
necessary to delineate thoroughly
the patient’s problem severity, to
identify comorbid or complicating 
medical or emotional conditions, and
to determine the appropriate 
treatment setting and level of
treatment intensity for the patient 
(CSAT, 2004). It is essential that
nurses perform assessments in a 
safe, confidential environment and
properly consider individuals’ and 
families’ race, gender, sexuality,
religion, and age (Clancy, Coyne, &
Wright, 1997). 
A comprehensive biopsychosocial 
assessment is necessary to determine 
the appropriateness of office-based or
other opioid-agonist treatment. The
assessment may be accomplished in 
stages over a 3- to 4-week period,
during initiation of treatment and
gradual acquisition of increasingly 
detailed information. Several office 
visits may be required to obtain all the 
information necessary to make a 
comprehensive set of diagnoses and to
develop an appropriate treatment 
plan, although these efforts also may 
be completed in a single, extended
visit. Treatment should not be 
delayed, however, pending complete 
patient assessment. The goals of a 
medical assessment of a patient who is 
addicted to opioids are to (CSAT, 
2004):
• Establish the diagnosis or diagnoses 
• Determine appropriateness for 
treatment 
• Make initial treatment 
recommendations 
• Formulate an initial treatment plan 
• Plan for engagement in
psychological treatment 
• Ensure that there are no 
contraindications to the 
recommended treatments 
• Assess other medical problems or
conditions that need to be addressed 
before or during early treatment 
• Assess other psychiatric or 
psychosocial problems that need to 
be addressed before or during early 
treatment 
Components of assessment. The 
components of assessment of a patient 
who is addicted to opioids should
include (CSAT, 2004): 
• Complete history. Complete
history includes substance abuse
history, addiction treatment history,
psychiatric history, family history, 
medical history, social and 
employment history, and readiness
for change. 
• Physical examination. Physical
examination should focus on 
physical findings related to 
addiction. The physical
complications of opioid addiction 
should be identified and addressed 
as part of the overall treatment
plan. 
• Mental status examination to 
evaluate the patient’s (CSAT, 2004): 
– General appearance 
– Behavior and interaction with 

interviewer 

– Speech and voice 
– Motor activity 
– Mood and affect 
– Perceptions, hallucinations, 

delusions 

– Thought process and content—
suicidal ideation, homicidal 
ideation, etc. 
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– Insight and judgment 
– Motivation and readiness to
change—patient’s stated goals and 
expectations 
– Cognitive function—orientation,
memory, attention, concentration, 
fund of information, literacy skills,
abstraction, intelligence 
– Personality characteristics 
– Defense mechanisms
– Relevant laboratory testing 
– Formal psychiatric assessment (if
indicated) (CSAT, 2005b) 
For additional information about 
components of a formal psychiatric 
assessment, refer to Mental Health 
Screening Form III (MHSF-III) (see 
Appendix D: Assessment
Instruments). 
Individuals who are addicted to opioids 
may have the same chronic diseases 
seen in the general population and 
should be evaluated, as appropriate, for
diseases that require treatment (such as 
infectious diseases, TB, and HIV). In 
addition, a number of medical 
conditions are commonly associated 
with opioid and other drug addictions 
(e.g., nutritional deficiencies and 
anemia, caused by poor eating habits;
hepatitis; and chronic obstructive 
pulmonary disease.) 
Assessing intoxication and
overdose. It is vitally important to
assess for signs of opioid intoxication, 
overdose, or withdrawal during the 
physical examination. Opioid overdose 
should be treated as a medical 
emergency. Opioid withdrawal can be 
objectively assessed by using several
instruments such as Clinical Institute 
Withdrawal Assessment for Alcohol,
Revised (CIWA-Ar) and Clinical
Institute Withdrawal Assessment for
Benzodiazepines(CIWA-B) (Kathleen 
Thompson-Gargano, personal
communication, October 2006) (see
Appendix D: Assessment Instruments).
For more information about screening 
tools, review the SAMHSA, CSAT, 
Treatment Improvement Protocol (TIP)
24, A Guide to Substance Abuse Services
for Primary Care Clinicians (CSAT, 
1997) (see
http://www.ncbi.nlm.nih.gov/books/
bv.fcgi?rid=hstat5.chapter.45293).
• Substances 
• Typical first symptoms  
• Patient education 
• Last substance use (dig deep to
determine what was used, how 
much, and when) 
• Withdrawal instrument score (e.g., 
COWS, in appendix D) 
• Precipitated withdrawal 
Diagnosis of Opioid-Related 
Disorders 
Health care providers should
document that every patient who is 
prescribed buprenorphine for the 
treatment of opioid addiction has met 
the criteria for opioid addiction 
(compulsive use of opioids despite 
harm), otherwise known as opioid
dependence as defined in the latest 
edition of the DSM-IV-TR (APA, 
2000). After a thorough assessment of
the patient has been conducted, a
formal diagnosis may be made using 
the DSM-IV-TR criteria for opioid and 
other substance dependence, and 
these criteria should be documented in 
the patient record by the licensed 
clinician who establishes the 
diagnosis. 
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In rare cases, a patient may be 
physiologically dependent on opioids
and meet DSM-IV-TR criteria for 
abuse but not for dependence. In such 
a case, a short course of
buprenorphine may be considered for
detoxification. Maintenance treatment 
with buprenorphine is not 
recommended for patients who do not 
meet DSM-IV-TR criteria for opioid
dependence. 
Determining 
Appropriateness for 
Buprenorphine Treatment 
Several issues should be considered in 
evaluating whether a patient is an 
appropriate candidate for
buprenorphine treatment of opioid
addiction in the office or other 
settings. At a minimum, candidates 
for buprenorphine treatment should: 
(1) be interested in treatment for 
opioid addiction, (2) have no absolute 
contraindication to buprenorphine, 
(3) be expected to be reasonably
compliant with such treatment, 
(4) understand the risks and benefits 
of buprenorphine treatment, (5) be 
willing to follow recommended safety 
precautions, and (6) consent to be 
treated with buprenorphine after a 
review of treatment options. It is
critical that the treatment approach 
be appropriate to the individual’s age,
gender, ethnicity, and culture (CSAT,
2004). 
Patients are less likely to be 
appropriate candidates for
buprenorphine treatment for opioid 
addiction if they have (1) comorbid 
dependence on high doses of
benzodiazepines or other central 
nervous system depressants (including 
alcohol), (2) significant untreated 
psychiatric comorbidity, (3) active or 
chronic suicidal or homicidal ideation 
or attempts, (4) multiple previous 
treatment episodes for drug abuse
with frequent relapses (except that
multiple previous detoxification
attempts followed by relapse are a
strong indication of the need for long-
term maintenance treatment), (5) poor 
response to previous treatment 
attempts with buprenorphine, and 
(6) significant medical complications 
(CSAT, 2004). 
Treatment Planning 
Nurses may be instrumental in the 
development of a treatment plan that 
contains (1) clear and achievable 
targets and time scales (e.g., number 
of sessions that a patient attends), 
(2) the venue in which 
care/intervention will be offered, and 
(3) the involvement of other services 
such as counseling and psychotherapy
(Clancy, Coyne, & Wright, 1997). Also, 
nurses must consider the patient’s 
motivation and treatment accessibility
throughout the treatment process. 
Nurses should actively involve 
patients in development of the
treatment plan, including discussing 
appropriate behavior, explaining
reasons for which medication may be 
discontinued, making a psychiatric 
referral or referral for other ancillary 
service, and explaining what happens
if a patient is noncompliant. Also,
patient participation in self-help 
support programs during and after 
treatment often is helpful in 
maintaining abstinence (Clancy,
Coyne and Wright, 1997).  
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Ongoing Treatment 
Monitoring 
Treatment must be assessed 
continually to ensure that it meets 
changing needs. Matching treatment
settings, interventions, and services to 
each individual’s particular problems 
and needs is critical to his or her 
ultimate success in returning to
productive functioning in the family, 
workplace, and society. No single
treatment is appropriate for all
individuals. Moreover, because 
individuals who are addicted to drugs 
may be uncertain about entering
treatment, taking advantage of
opportunities when they are ready for
treatment is crucial. Treatment must 
be readily available. Potential
treatment applicants can be lost if
treatment is not immediately 
available or is not readily accessible 
(CSAT, 2004). 
To be effective, treatment must
address the individual’s drug use and 
any associated medical, psychological, 
social, vocational, and legal problems. 
In addition to medication, the person
may require varying combinations of
services and treatment components, 
including counseling or
psychotherapy, medical services,
family therapy, parenting instruction, 
vocational rehabilitation, and social 
and legal services. Remaining in 
treatment for an adequate period of 
time is critical for treatment 
effectiveness. However, appropriate 
duration depends on problems and 
needs. For most patients, the
threshold of significant improvement 
is about 3 months in treatment. 
Because people often leave treatment 
prematurely, it is necessary for the
treatment team to plan strategies to 
engage and keep patients in
treatment. (CSAT, 2004). 
It is crucial for nurses to monitor 
patients before and during the 
induction phase. Possible drug use
during treatment must be monitored 
continuously, as it is not unusual for
relapses to occur during treatment. 
Objective monitoring (urinalysis and 
other tests) helps patients withstand 
urges to use. Monitoring can provide
early evidence of drug use so that the 
treatment plan can be adjusted.
Finally, feedback to patients who test
positive for illicit drug use is an 
important element of monitoring
(Clancy, Coyne, & Wright, 1997). 
Before treatment induction, nurses
should review the following 
instructions with patients to prepare 
them for the first day of induction:  
• Come to the doctor’s office in mild 
withdrawal. 
• Dispose of all illicit drugs and 
paraphernalia before the visit. 
• Do not plan to drive for 24 hours
after receiving the first dose(s) of 
buprenorphine medication. 
• Plan to be at clinic or office for up to 
4 hours, because induction may
involve monitoring and more than 
one dose of medication (patient may 
bring a sandwich, book, etc.). 
• Be ready to give a urine sample. 
• Put tablet(s) under tongue and allow
the tablet(s) to dissolve slowly. 
• Do not talk, eat, drink, or swallow 
while the medication is in mouth. 
• May a use mirror and watch the
tablet(s) gradually shrink as they
dissolve (Labelle, 2006).  
When dispensing the first medication
dose, it is crucial that nurses (1) watch 
the patient put the tablet in the right
place under the tongue, (2) check 
periodically to see the tablet 
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shrinking, and (3) check that the table 
is completely gone. This is the only 
way of telling that ingestion occurred, 
aside from urine testing for 
buprenorphine (LaBelle, 2006). 
The patient should receive a daily dose 
until stabilized. Once stabilized, the 
patient may continue a single daily 
dose or may shift to alternate-day 
dosing (e.g., every other day or 
Monday, Wednesday, Friday) (Amass
et al., 2001). Also, providers can
increase the dose on the dosing day by 
the amount not received on 
intervening days. For example, if the 
patient stabilizes on 8 mg daily, and 
every-other-day dosing is desired, then 
the provider may change the dosage to
16 mg on Monday, 16 mg on
Wednesday, and 24 mg on Friday (to
provide medication coverage for the 
2-day weekend).  
Counseling and Referral for 
Psychosocial Treatment 
DATA 2000 stipulates that when a
physician submits a notification (form 
SMA-167) to SAMHSA for a
buprenorphine waiver, the physician
must attest to the capacity to refer 
patients for appropriate counseling 
and other nonpharmacological
therapies. Physicians who are
providing opioid treatment should 
ensure that they are capable of 
providing psychosocial services either
in their own practices (including 
counseling and patient participation 
in self-help groups) or through 
referrals to reputable behavioral 
health practitioners in their 
communities. 
During consultation, nurses and other
health care providers must pay
attention to all patients’ medical and 
psychosocial comorbidities and 
address them comprehensively, as 
pharmacotherapy rarely achieves
long-term success without concurrent
psychosocial, behavioral therapies and
social services. Also, special attention 
must be given to those patients at risk 
of misusing their medications or 
whose living arrangements pose
increased risk for misuse or diversion. 
Counseling (individual or group) and
other behavioral therapies are critical
components of effective treatment. In
therapy, patients must be helped to 
(1) address motivation, (2) build skills 
to resist drug use, (3) replace drug-
using activities with constructive and 
rewarding nondrug-using activities,
(4) improve problemsolving abilities, 
(5) work on interpersonal 
relationships, and (6) improve family 
and community functioning. 
Addicted or drug-abusing individuals 
with coexisting mental disorders 
should have both disorders treated in 
an integrated way since substance use 
disorders (SUDs) and mental 
disorders often co-occur. Additionally, 
patients presenting for either 
condition should be assessed and 
treated for the co-occurrence of the 
other type of disorder. Treatment 
providers should assess and counsel 
individuals about HIV/AIDS, hepatitis 
B and C, TB, and other infectious
diseases in order to (1) avoid high-risk 
behavior and (2) help people who are
already infected to manage their 
illness (CSAT, 2004). 
Categories of special populations who
are highly in need of consultation
while in treatment include the 
following (CSAT, 2004):  
• Patients with psychiatric
comorbidity require specialized
assessment and integrated 
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treatment. 

• Patients with pain need regular 
medical care (not an OTP) if they 
are diagnosed with a pain disorder 
but not with addiction. Patients with 
pain disorders are sometimes 
physically dependent on medication.
Patients with pain and patients with
co-occurring addiction and chronic or 
acute pain may need to be assessed
by a pain management specialist as 
well as an addiction specialist. 
• Patients with medical comorbidities 
(such as infectious diseases or other
medical complications) may 
additionally require referrals to one
or a number of medical specialties.  
• Patients who are pregnant and have 
opioid or other addictions are high-
risk patients and require specialized 
care to manage and reduce risks for 
both the mothers and the neonates. 
However, information on 
buprenorphine and pregnancy is
limited. 
• Adolescent patients have special 
psychosocial and educational needs,
and they require special consent 
procedures for starting treatment. 
• Geriatric patients have particular
vulnerabilities, but information 
about buprenorphine and older
adults is limited.  
• Patients with polysubstance abuse
should be referred to addiction 
specialists (buprenorphine is not
known to be effective for treating
addiction to drugs in other classes). 
• Patients who are recently
discharged from, or under the 
jurisdiction of, the criminal justice 
system require collateral and other 
reporting contacts (for example, 
phone calls or written reports for 
parole officers or the drug court). 
Additionally, these patients may 
have other comorbid health, mental
health, or psychosocial issues; they
should receive services to stabilize 
these aspects of their lives. 
• Health care professionals with 
addiction require comprehensive,
specialized care. Their recovery plan 
must be closely monitored, and 
reporting to State authorities may
be required. 
Treatment Retention and 
Relapse Prevention 
Length of buprenorphine treatment
may be as short as a few days for
medically supervised withdrawal or as 
long as several years for maintenance 
therapy. Recovery from drug addiction 
can be a long-term process and
frequently requires multiple episodes
of treatment. As with other chronic 
illnesses, relapses may occur during or 
after successful treatment episodes. 
Individuals may require multiple 
episodes of prolonged treatment to
achieve long-term abstinence and fully 
restored functioning. Nurses must 
continuously monitor urine drug
testing or other toxicology testing, the
number of pills in the patient’s supply,
medication dosage, and pharmacy 
checks to help prevent relapse.
Relapse can happen because of the
presence of both physical and 
emotional triggers in the patient’s life. 
Nurses must help patients understand 
those triggers and create strategies to 
avoid and manage them (Marlatt & 
George, 1984; Wanigaratne et al., 
1990). Those strategies include
(1) help patients develop an 
understanding of the stressful triggers 
in their lives, (2) help patients develop 
alternative adaptive responses to
stresses, and (3) help them find 
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constructive ways of managing stress
(Clancy, Coyne, & Wright, 1997). 
Nurses and other health care 
providers must continuously ask
patients open questions to facilitate 
constructive discussion rather than 
resistance. Examples of those
questions are as follows: 
• What do you think you will do? 
• It must be uncomfortable for you.
What is your next step? 
• What are your options? 
• What are some of the good things
happening to you? 
• What is changing in your life? 
• How does it feel to be successful 
thus far? (Clancy, Coyne, & Wright, 
1997) 
• What can we do to help you in your 
recovery process? 
• What has worked for you in the
past? 
The aim of nursing intervention in
recovery management is to help
patients prioritize their needs and 
maintain their motivation as well as 
to empower patients to achieve desired 
recovery outcomes (Clancy, Coyne, &
Wright, 1997). 
Nurses must focus on patients’ 
empowerment and help them manage
their lives in a constructive way
(Seedhouse, 1986). Nurses also need to
help patients (1) develop trust over 
time during their therapeutic visits, 
and develop further trust of the 
treatment program and providers; 
(2) identify their own needs, and
verbalize their specific goals and
objectives; and (3) achieve their plans
successfully (Egan, 1990). 
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Title 42 Code of Federal 
Regulations, Part 2, Subpart 
C—Disclosures With 
Patient’s Consent 
Prior to initiating office-based opioid 
addiction treatment, practice policies and 
procedures should be established that 
will guarantee the privacy and 
confidentiality of patients treated for 
addiction. Providers must comply with 
all applicable laws and regulations 
regarding the privacy and confidentiality
of medical records in general, and of
information pertaining to addiction 
treatment services in particular. The 
privacy and confidentiality of
individually identifiable information 
relating to patients receiving drug or 
alcohol treatment is protected by the
SAMHSA confidentiality regulation, 
Title 42, Part 2 of the Code of Federal
Regulations (42 CFR Part 2). This
regulation mandates that addiction
treatment information in the possession 
of substance abuse treatment providers 
be handled with a greater degree of 
confidentiality than general medical 
information. Occasionally, physicians 
will need to communicate with
pharmacists and other health care
providers about the addiction treatment 
of a particular patient (e.g., to verify a
Suboxone® or Subutex® prescription). 
Regulation 42 CFR Part 2 requires
physicians providing opioid addiction 
treatment to obtain a signed patient 
consent before disclosing individually 
identifiable addiction treatment
information to any third party. A sample 
consent form with all the elements 
required by 42 CFR Part 2 is included in 
TIP 40, pages 119–120 (CSAT, 2004).
Here is the link to the consent form:  
http://www.ncbi.nlm.nih.gov/
books/bv.fcgi?rid=hstat5.section.72974. 
Physicians should have each new 
patient who is treated with 
buprenorphine sign a copy of this form
to prevent confidentiality problems at 
pharmacies when patients present 
with buprenorphine prescriptions. It is
particularly important to obtain
patients’ consent when telephoning or 
faxing prescriptions to pharmacies, as 
this information constitutes disclosure
of the patient’s addiction treatment. 
When physicians directly transmit
prescriptions to pharmacies, further 
redisclosure of patient-identifying 
information by the pharmacy is
prohibited, unless signed patient
consent is obtained by the pharmacy.
Regulation 42 CFR Part 2 does not 
apply to pharmacies, however, when
the patient delivers a buprenorphine 
prescription without telephone 
confirmation or other direct 
communication from physicians to the
pharmacist. 
The Health Insurance Portability and
Accountability Act (HIPAA) of 1996,
Public Law 104-191 
(http://aspe.hhs.gov/admnsimp/pl1041
91.htm), which amends the Internal 
Revenue Service Code of 1986, 
mandates standardization of exchange 
formats for patient health, 
administrative, and financial data; 
requires development of unique
identifiers for individuals, employers, 
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health plans, and health care
providers; and establishes security 
standards for protecting the 
confidentiality and integrity of
individually identifiable health
information. SAMHSA has prepared a 
document—Comparison Between the
Confidentiality of Alcohol and 
Substance Abuse Patient Records 
(42 CFR Part 2) and the Health
Insurance Portability and
Accountability Act 1996—that is 
available, along with other HIPAA
technical assistance tools, on the 
SAMHSA HIPAA Web pages at
http://www.hipaa.samhsa.gov. See also 
the SAMHSA Treatment Assistance 
Publication (TAP) 13, Confidentiality 
of Patient Records for Alcohol and 
Other Drug Treatment (Lopez, 1994),
available on the SAMHSA Treatment 
Improvement Exchange Web site at
http://www.treatment.org/taps/index.
html. The Subutex® and Suboxone® 
package labels (available on the FDA
Web site at
http://www.fda.gov/cder/drug/infopage/
subutex_suboxone/default.htm) also
contain information on Federal 
confidentiality rules and regulations. 
Physicians, nurses, and other health
care providers should also consult 
with their State medical authorities 
concerning privacy and confidentiality
rules in their locales. Some of the 
privacy and confidentiality issues that 
can arise in the course of addiction 
treatment (CSAT, 2004) are: 
• Information covered by the
doctor/patient privilege 
• Circumstances in which confidential 
information is protected from
disclosure
• Exceptions to State laws protecting 
ethical information 
• Duty to report potential threats of 
violence or child or elder abuse 
• Communications with third parties
(e.g., families, employers, allied 
health care providers, third-party 
payers, law-enforcement officers, 
responses to subpoenas)  
Nurses are responsible for assuring 
patients that their personal 
information is safe and respected 
within the team and agency. Also,
nurses must inform patients that their 
personal information can be provided
to third parties on the patient’s behalf 
only with written permission from the 
patient (Lambert & Coyne, 1993; 
UKCC, 1996). 
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For More Information 

Center for Substance Abuse 
Treatment (CSAT) Buprenorphine
Information Center
http://www.buprenorphine.samhsa.gov/
Telephone: 866–BUP–CSAT
(866–287–2728); live operators are
available to answer calls Monday 
through Friday from 8:30 a.m. to
5:00 p.m., EST.
SAMHSA Buprenorphine
Physician Locator Web Site  
http://buprenorphine.samhsa.gov/
bwns_locator/index.html
E-mail: 
info@buprenorphine.samhsa.gov. 
Federation of State Medical Boards 
(FSMB)
Model Policy Guidelines for Opioid 
Addiction Treatment in the Medical 
Office
http://www.fsmb.org/grpol_policydocs.
html
Food and Drug Administration
(FDA)/Center for Drug Evaluation
and Research (CDER) 
Telephone: 888–INFO–FDA for
consumer inquiries and 301–827–6242
for media inquiries. 
http://www.fda.gov/cder/drug/infopage/
subutex_suboxone/default.htm
Join Together: National Poll of
Physicians on Barriers to 
Widespread Buprenorphine Use 
http://www.jointogether.org/sa/
issues/hot_issues/bupe/
National Association of State 
Alcohol and Drug Abuse
Directors (NASADAD)
NASADAD Policy Paper 14 (Topic: 
The Use of Medications in 
Substance Abuse Treatment) 
http://www.nasadad.org/resource.
php?doc_id=35
NASADAD Policy Paper 15 (Topic: 
Physician Information—Answers to
Frequently Asked Questions) 
http://www.nasadad.org/
resource.php?doc_id=75
Northwest Frontier Addiction 
Technology Transfer Center
(ATTC), Opiate Medication 
Initiative for Rural Oregon
Residents (OMIROR). November
2003. 
Treating Opiate Dependence in
Rural Communities: A Guide for 
Developing Community Resources.
http://www.ireta.org/opiates2005/
10.pdf
Substance Abuse and Mental 
Health Services Administration 
(SAMHSA)
Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of
Opioid Addiction, Treatment 
Improvement Protocol (TIP #40),
available through SAMHSA’s 
National Clearinghouse on Alcohol
and Drug Information (NCADI). To
order, go to http://ncadistore.
samhsa.gov/catalog/productDetails.
aspx?ProductID=16829. Telephone:
1–800–729–6686. 
Suboxone® Clinical Information 
Hotline and Website 
Telephone: 877–SUBOXONE 
(1–877–782–6966); Web:
http://www.suboxone.com
The National Alliance of Advocates for 
Buprenorphine Treatment
(NAABT)
http://www.naabt.org
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Training Sessions 

You may contact the Suboxone® help
line (1–877–782–6966) or visit the
Suboxone® Web site 
(http://www.suboxone.com), or you 
may contact any of the following
organizations: 
The American Academy of Addiction
Psychiatry
7301 Mission Road, Suite 252
Prairie Village, KS 66208 
Telephone: 913–262–6161
E-mail: info@aaap.org
Web site: http://www.aaap.org
The American Psychiatric Association
1400 K Street, NW.
Washington, DC 20005 
Telephone: 888–357–7924
E-mail: apa@psych.org
Web site: http://www.psych.org
The American Society of Addiction
Medicine 
4601 North Park Avenue, Arcade
Suite 101 
Chevy Chase, MD 20815
Telephone: 301–656–3920
E-mail: email@asam.org
Web site: http://asam.org
American Osteopathic Association
142 East Ontario Street 
Chicago, IL 60611
Telephone: 800–621–1773
E-mail: 1info@aoa-net.org
Web site: http://www.aoa-net.org
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Welcome to the Buprenorphine Physician and  
Treatment Program Locator 
The Locator is a service of the Center for Substance Abuse Treatment (CSAT), 
Substance Abuse and Mental Health Services Administration (SAMHSA).  
The Locator is an online resource designed to assist States, medical and addiction 
treatment communities, potential patients, and/or their families in finding 
information on locating physicians and treatment programs authorized to treat 
opioid addiction with buprenorphine (Suboxone® and Subutex®).  
The Locator lists:  
• Physicians authorized to prescribe a class of medications for opioid (narcotic) 
addiction treatment, of which Suboxone® and Subutex® are the only ones 
approved at this time. 
• Treatment programs authorized to dispense (but not prescribe) opioid treatment 
medications, including Suboxone® and Subutex®.  
The treatment programs in the Locator are based on a list of treatment programs 
authorized under 21 U.S. Code (U.S.C.) Section 823(g)(1) to dispense (but not 
prescribe) opioid treatment medications. These treatment programs can admit 
patients and dispense methadone, Subutex®, or Suboxone®. Please note that CSAT 
is not a treatment referral agency and cannot make specific recommendations or 
endorsements regarding treatment programs on the Locator.  
CSAT compiles the list of physicians in the Locator from its information on qualified 
physicians who have waivers to prescribe or dispense specially approved classes of 
narcotic medications for the treatment of narcotic addiction. Of these drugs, 
Subutex® and Suboxone® are the only ones approved by the U.S. Food and Drug 
Administration (FDA) thus far. The list includes only physicians who have met 
qualifications under the Drug Addiction Treatment Act of 2000 (DATA 2000) and 
who have authorized the use of their names in the Locator. As noted above for 
treatment programs, CSAT cannot make specific recommendations or endorsements 
regarding physicians on the Locator.  
DATA 2000 allows qualified physicians to dispense or prescribe specially approved 
Schedule III, IV, and V drugs for medication-assisted opioid addiction treatment. In 
addition, DATA 2000 reduces the regulatory burden on physicians who choose to 
practice opioid therapy by permitting qualified physicians to apply for and receive 
waivers of the special registration requirements defined in the Narcotic Addiction 
Treatment Act and the Controlled Substances Act. Since DATA 2000 was enacted in 
October 2000, only the partial opioid agonist medication buprenorphine (Suboxone® 
and Subutex®) has received FDA approval.  
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To read the text of DATA 2000, to view what is required of “qualifying physicians” 
under the act, or to find out more about buprenorphine and DATA 2000, follow this 
link. http://www.buprenorphine.samhsa.gov/bwns_locator/aboutphysician.htm 
How buprenorphine works is explained at 
http://www.naabt.org/education/images/Receptors_HiRes.jpg 
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(Illustration provided by the National Alliance of Advocates for Buprenorphine 
Treatment, copyright 2007, NAABT, Inc.) 
Opioid receptor is empty. As someone becomes tolerant to opioids, they become less 
sensitive and require more opioids to produce the same effect. Whenever there is an 
insufficient amount of opioid receptors activated, the patient feels discomfort. This 
happens in withdrawal. 
Opioid receptor filled with a full-agonist. The strong opioid effect of heroin and 
painkillers can cause euphoria and stop the withdrawal for a period of time 
(4-24 hours). The brain begins to crave opioids, sometimes to the point of an 
uncontrollable compulsion (addiction), and the cycle repeats and escalates. 
Opioids replaced and blocked by buprenorphine. Buprenorphine competes with the 
full agonist opioids for the receptor. Since buprenorphine has a higher affinity 
(stronger binding ability) it expels existing opioids and blocks others from attaching. 
As a partial agonist, the buprenorphine has a limited opioid effect, enough to stop 
withdrawal but not enough to cause intense euphoria. 
Over time (24–72 hours) buprenorphine dissipates, but still creates a limited opioid 
effect (enough to prevent withdrawal) and continues to block other opioids from 
attaching to the opioid receptors. 
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Figure 1. Induction Days 1–2 
 
Repeat dose up to maximum
8 mg per 24 hours
Repeat dose up to maximum
8/2 mg per 24 hours
Administer 4/1 mg
buprenorphine/naloxone.
Observe 2+ hours
Manage withdrawal 
symptomatically
Patient dependent 
on opioids
No
Return next day for 
repeat induction attempt
(see figure 2)
Reevaluate suitability 
for induction
Yes
Yes
Administer 2 mg 
buprenorphine monotherapy.
Observe 2+ hours
Day 1 dose established
(see figure 2)
Yes
No
Long-acting opioids
Methadone: Taper to 
≤30 mg per day
LAAM: Taper to 
≤40 mg per 48-hour dose
No
Yes
Withdrawal 
symptoms 
relieved?
Yes
Withdrawal 
symptoms 
relieved?
Short-acting opioids
Withdrawal 
symptoms
present 
12–24 hours 
after last dose of 
opioids?
No
Discontinue 
short-acting opioids
Withdrawal 
symptoms 
relieved?
No
Day 1 dose established
(see figure 2)
Methadone: 
Withdrawal 
symptoms 24+ hours 
after last dose?
LAAM: Withdrawal 
symptoms 48+ hours 
after last 
dose?
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When a patient dependent on opioids presents for treatment, determine whether 
the drug is a long-acting or short-acting opioid. The withdrawal and buprenorphine 
induction process is described here separately for these types of opioids. 
If a patient presents who is taking the long-acting opioid methadone, taper the dose 
to 30 milligrams or less per day. If patient is taking the long-acting opioid 
levomethadyl acetate (LAAM), taper dose to 40 milligrams or less per 48 hours.  
If a patient is not experiencing withdrawal symptoms 24 or more hours after the 
last dose of methadone or 48 hours or more after the last dose of LAAM, reevaluate 
the patient’s suitability for induction of buprenorphine treatment. If the patient is 
experiencing symptoms of withdrawal from these drugs at these time intervals, 
administer 2 milligrams of buprenorphine monotherapy and observe the patient for 
2 hours or longer. 
If administering buprenorphine relieves withdrawal symptoms, the dose for day 1 is 
established (see figure 2 for details of further treatment). 
If withdrawal symptoms are not relieved, repeat the dose of 2 milligrams of 
buprenorphine monotherapy, up to a maximum of 8 milligrams per 24 hours.  
If the larger dose relieves withdrawal symptoms, the day 1 dose is established 
(continue treatment as described in figure 2). 
If the larger dose does not relieve symptoms, manage withdrawal symptomatically 
and have the patient return the next day for a repeat of the attempt to induce 
buprenorphine treatment. 
If a patient presents who is taking a short-acting opioid, discontinue the opioid. 
If withdrawal symptoms are not present 12–24 hours after the last dose of opioids, 
reevaluate the person’s suitability for induction of buprenorphine treatment. 
If withdrawal symptoms are present within 12–24 hours after the last dose of 
opioids, administer of a dose of 4 milligrams buprenorphine combined with 
1 milligram of naloxone; observe the patient for 2 hours or longer. If withdrawal 
symptoms are relieved, the Day 1 dose has been established. Continue as described 
in figure 2. 
If withdrawal symptoms are not relieved with the combined dose above, repeat the 
dose up to a maximum of 8 milligrams of buprenorphine combined with 
2 milligrams of naloxone per 24 hours. If withdrawal symptoms are relieved with 
this higher dose, the day 1 dose is established. Continue treatment as described in 
figure 2. 
If the larger dose does not relieve symptoms, manage withdrawal symptomatically 
and have the patient return the next day for a repeat of the attempt to induce 
buprenorphine treatment. 
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Figure 2. Induction Day 2 Forward 
 
No
Patient returns to office on 
buprenorphine/naloxone*
Administer dose equal to the total amount of 
buprenorphine/naloxone administered on
previous day plus an additional 4/1 mg
(maximum 12/3 mg on Day 2). Observe 2+ hours
Daily buprenorphine/naloxone 
dose established**
Daily dose established equal to
total buprenorphine/naloxone
administered on previous day**
Yes
On subsequent induction days, if the patient 
returns experiencing withdrawal symptoms, 
continue dose increases as per the schedule 
shown above, up to a maximum of  
32/8 mg buprenorphine/naloxone per day.†
No
*If buprenorphine monotherapy was administered on Day 1, switch to buprenorphine/naloxone on 
Day 2 (for a patient who is not pregnant). 
**Dose may be increased by 2/0.5–4/1 mg increments on subsequent days as needed for symptom 
relief. Target dose of 12/3–16/4 mg buprenorphine/naloxone per day by the end of the first week.
†More recent clinical data suggest that daily doses above 24 mg of buprenorphine do not provide 
additional therapeutic benefit to the vast majority of patients.
Yes
Withdrawal 
symptoms present 
since last dose?
Withdrawal 
symptoms relieved?
Manage withdrawal symptomatically
Withdrawal 
symptoms relieved?
Administer 4/1 mg buprenorphine/naloxone 
(maximum 16/4 mg total on Day 2)
No
Yes
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When a patient returns to the office on Day 2, having taken on Day 1 
buprenorphine monotherapy (if formerly taking long-acting opioids) or combination 
buprenorphine and naloxone therapy (if formerly taking a short-acting opioid), 
switch to the combination therapy on Day 2 (if the patient is not pregnant).  
If the patient is not having withdrawal symptoms since the last therapy (Day 1), 
administer the daily dose equal to the combination therapy administered on day 1. 
Note that the dose may be increased by 2–4 milligrams buprenorphine and  
0.5–1 milligrams naloxone on subsequent days, as needed for symptom relief. 
Target a dose to reach 12–16 milligrams buprenorphine combined with  
3–4 milligrams naloxone per day by the end of the first week.  
If the patient is having withdrawal symptoms since the last dose of therapy on 
Day 1, administer a dose equal to the total amount of combined therapy 
administered the previous day plus an additional 4 milligrams buprenorphine and 
1 milligram naloxone. The maximum dose for Day 2 is 12 milligrams buprenorphine 
and 3 milligrams of naloxone. Observe the patient for 2 hours or longer. 
If the withdrawal symptoms are relieved, the daily buprenorphine and naloxone 
combined dose is established. Again, note that the dose may be increased by  
2–4 milligrams buprenorphine and 0.5–1 milligrams naloxone on subsequent days, 
as needed for symptom relief. Target a dose to reach 12–16 milligrams 
buprenorphine combined with 3–4 milligrams naloxone per day by the end of the 
first week.  
If the withdrawal symptoms are not relieved with the dose given on Day 1, 
administer an additional dose of combined 4 milligrams buprenorphine and 
1 milligram naloxone. The maximum total dose on day 2 is 16 milligrams 
buprenorphine and 4 milligrams naloxone.  If withdrawal symptoms are relieved, 
the new daily dose is established. Again, note that the dose may be increased by  
2–4 milligrams buprenorphine and 0.5–1 milligrams naloxone on subsequent days, 
as needed for symptom relief. Target a dose to reach 12–16 milligrams 
buprenorphine combined with 3–4 milligrams naloxone per day by the end of the 
first week. 
If the increased dose on Day 2 does not relieve withdrawal symptoms, manage 
withdrawal symptomatically. On subsequent induction days, if the patient returns 
experiencing withdrawal symptoms, continue to increase the doses as per the 
schedule above up to a daily maximum of 32 milligrams buprenorphine and 
8 milligrams naloxone combined. 
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Figure 3. Stabilization Phase 
 
Yes
No
No
Maintain on buprenorphine/naloxone dose. 
Increase intensity of nonpharmacological
interventions. Consider referral to OTP or 
other more intense level of treatment
Daily dose of buprenorphine/
naloxone established
Induction phase 
completed?
Patient receiving induction
Continued
illicit opioid use?
Withdrawal
symptoms
present?
Compulsion
to use, cravings 
present?
Continue adjusting dose up
to 32/8 mg buprenorphine/
naloxone per day*
Yes
Yes
No
Continued 
illicit opioid use 
despite maximum 
dose?
No No
Yes
Yes
*More recent clinical data suggest that daily doses above 24 mg of buprenorphine do not provide 
additional therapeutic benefit to the vast majority of patients.
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If a patient is receiving induction, this phase is completed when the daily dose of 
combined buprenorphine and naloxone is established and the patient has not 
continued illicit opioid use, withdrawal symptoms are not present, and neither the 
compulsion to use drugs nor cravings are present.  
If a patient is receiving induction, this phase is not completed if the patient has 
continued illicit opioid use, withdrawal symptoms are present, and the compulsion 
to use drugs or cravings are present. If any of these conditions or more than one is 
present, continue adjusting the combined daily dose up to 32 milligrams 
buprenorphine and 8 milligrams naloxone. If the patient does not continue illicit 
opioids use, this dose becomes the established combined daily dose.  
If the patient does continue illicit opioid use despite the maximum combined dose, 
maintain that combined dose. Increase the intensity of nonpharmacological 
interventions. Consider referral to Opioid Treatment Programs or other more 
intense levels of treatment.  
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Figure 4. Detoxification From Short-Acting Opioids 
 
Taper buprenorphine
over 3–6 days
No Yes
Yes
No Yes
No
Patient dependent on 
short-acting opioids
Discontinue short-acting opioids. 
Administer 
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buprenorphine/naloxone
Continue taper Discontinue taper until patientstabilizes, then resume
Withdrawal
symptoms
emerge?
Adjust dose to relieve 
withdrawal symptoms
(see figure 1)
Stabilize on appropriate
dose for at least 2 days
Compelling 
reason for rapid
discontinuation 
of opioids?
Stabilize on 
buprenorphine/naloxone
(1 week or longer)
Taper buprenorphine/naloxone 
over moderate-period or 
long-period (preferred) reduction
Withdrawal 
symptoms emerge?
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If a patient is dependent on short-acting opioids, discontinue those drugs and 
administer combined 4 milligrams buprenorphine and 1 milligram naloxone. 
If withdrawal symptoms emerge, adjust the dose of combined buprenorphine and 
naloxone to relieve withdrawal symptoms, as described in figure 1. 
If withdrawal symptoms do not emerge (or the dose of combined drugs relieves 
withdrawal symptoms) stabilize the patient on the appropriate dose of 
buprenorphine/naloxone for at least 2 days.  
If there is a compelling reason for rapid discontinuation of opioids, taper 
buprenorphine over 3–6 days, then continue buprenorphine/naloxone. 
If there is not a compelling need for rapid discontinuation of opioids, stabilize the 
patient’s dose of buprenorphine/naloxone for 1 week or longer. Taper the combined 
buprenorphine/naloxone over a moderate period, or preferably a long period, of 
reduction in dose.  
If withdrawal symptoms emerge, discontinue the taper until the patient stabilizes, 
then resume tapering. If withdrawal symptoms do not emerge, or after taper is 
resumed, continue taper until buprenorphine/naloxone treatment is discontinued. 
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Figure 5. Discontinuing of Opioid Agonist Treatment (OAT) Using Buprenorphine 
 
Compelling
reason to discontinue
methadone or
LAAM?
No
Yes
Yes
Yes
No
Patient being treated with methadone 
or LAAM; displays evidence of medical 
and psychosocial stability
Continue current treatment
Taper buprenorphine monotherapy
over 3–6 days, then discontinue
Discontinue buprenorphine/naloxone
Methadone: 
Taper to ≤30 mg per day
LAAM: 
Taper to ≤40 mg per 48-hour dose
Buprenorphine monotherapy induction 
(see figure 1)
Compelling reason 
for rapid discontinuation?Switch to buprenorphine/naloxone
Stabilize on buprenorphine/naloxone
(1+ weeks)
Taper buprenorphine/naloxone
(2+ weeks)
Withdrawal symptoms emerge?
No
Split into 2–3 smaller doses per day 
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66 
If a patient who is being treated with methadone or levomethadyl acetate (LAAM) 
displays evidence of medical and psychosocial stability, consider whether there is a 
compelling reason to discontinue that treatment. If not, continue with that 
treatment. 
If there is a compelling reason to discontinue that treatment, taper doses 
(methadone to 30 milligrams or less per day or less; LAAM to 40 milligrams or less 
per day). 
When the patient has tapered to those doses, begin buprenorphine monotherapy 
(see figure 1). 
If there is a compelling reason for rapid discontinuation of therapy, taper 
buprenorphine monotherapy over 3–6 days, then discontinue. 
If there is not a compelling reason for rapid discontinuation after induction of 
buprenorphine monotherapy, switch to combined buprenorphine/naloxone therapy 
and stabilize the dose over a period of 1 week or more.  
Then taper the combined buprenorphine/naloxone therapy over 2 or more weeks. If 
withdrawal symptoms emerge, split the total amount into 2–3 smaller doses per 
day.  
When withdrawal symptoms do not emerge, discontinue the combined 
buprenorphine/naloxone therapy.  
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Drug Abuse Screening Test (DAST-10), Drug Use Questionnaire 
The following questions concern information about your possible involvement with 
drugs, not including alcoholic beverages, during the past 12 months. Carefully read 
each statement and decide if your answer is “Yes” or “No.” Then circle the 
appropriate response beside the question.  
In the following statements “drug abuse” refers to 
• The use of prescribed or over-the-counter drugs in excess of the directions, and 
• Any nonmedical use of drugs.  
• The various classes of drugs may include cannabis (e.g., marijuana, hashish), 
solvents (e.g., paint thinner), tranquilizers (e.g., Valium), barbiturates, cocaine, 
stimulants (e.g., speed), hallucinogens (e.g., lysergic acid diethylamide [LSD]), or 
narcotics (e.g., heroin). Remember that the questions do not include alcoholic 
beverages. 
Please answer every question. If you have difficulty with a question, then choose the 
response that is mostly right. 
These Questions Refer to the Past 12 Months 
1. Have you used drugs other than those required for medical reasons? Yes No 
2. Do you abuse more than one drug at a time? Yes No 
3. Are you always able to stop using drugs when you want to? Yes No 
4. Have you ever had blackouts or flashbacks as a result of drug use? Yes No 
5. Do you ever feel bad or guilty about your drug use? Yes No 
6. Does your spouse (or parents) ever complain about your involvement with drugs? Yes No 
7. Have you neglected your family because of your use of drugs? Yes No 
8. Have you engaged in illegal activities in order to obtain drugs? Yes No 
9. Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking 
drugs? 
Yes No 
10. Have you had medical problems as a result of your drug use  
(e.g., memory loss, hepatitis, convulsions, bleeding)? 
Yes No 
Interpretation (Each “Yes” response = 1) 

Score Degree of Problems Related to Drug Abuse Suggested Action 
0 No Problems Reported None At This Time 
1–2 Low Level Monitor, Reassess At A Later Date 
3–5 Moderate Level Further Investigation 
6–8 Substantial Level Intensive Assessment 
Source: Adapted from Skinner, H. A. (1982). The drug abuse screening test. Addictive Behaviors, 7(4),
363–371. Copyright 2008. Reprinted with permission from Centre for Addiction and Mental Health.
Available online at http://www.drugabuse.gov/Diagnosis-Treatment/DAST10.html. 
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The Alcohol Use Disorders Identification Test (AUDIT): Interview Version 
1. How often do you have a drink* containing alcohol? 
□ Never (0) [Skip to Questions 9–10] 
□ Monthly or less (1) 
□ 2 to 4 times a month (2) 
□ 2 to 3 times a week (3) 
□ 4 or more times a week (4) 
2. How many drinks containing alcohol do you have on a typical day when you are 
drinking? 
□ 1 or 2 (0) 
□ 3 or 4 (1) 
□ 5 or 6 (2) 
□ 7, 8, or 9 (3) 
□ 10 or more (4) 
3. How often do you have six or more drinks on one occasion? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
[Skip to Questions 9 and 10 if Total Score for Questions 2 and 3 = 0] 
4. How often during the last year have you found that you were unable to stop 
drinking once you had started? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
5. How often during the last year have you failed to do what was normally expected 
of you because of drinking? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
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6. How often during the last year have you needed a first drink in the morning to 
get yourself going after a heavy drinking session? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
7. How often during the last year have you had a feeling of guilt or remorse after 
drinking? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
8. How often during the last year have you been unable to remember what 
happened the night before because you had been drinking? 
□ Never (0) 
□ Less than monthly (1) 
□ Monthly (2) 
□ Weekly (3) 
□ Daily or almost daily (4) 
9. Have you or someone else been injured as the result of your drinking? 
□ No (0) 
□ Yes, but not in the last year (1) 
□ Yes, during the last year (2) 
10.Has a relative, friend, or a doctor or other health worker been concerned about 
your drinking or suggested you cut down? 
□ No (0) 
□ Yes, but not in the last year (1) 
□ Yes, in the last year (2) 
Record the total of the specific items. _____ 
* In determining the response categories it has been assumed that one drink contains 
10 g alcohol. In countries where the alcohol content of a standard drink differs by more 
than 25 percent from 10 g, the response category should be modified accordingly. 
Source: Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). AUDIT. 
The Alcohol Use Disorders Identification Test: Guidelines for use in primary care. 2nd ed. 
Geneva: WHO, Department of Mental Health and Substance Dependence. 
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Available at http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf
A self-report version of the AUDIT is also available in Babor et al. 2001. 
Scoring and Interpretation of the AUDIT 
The minimum score (for nondrinkers) is 0 and the maximum possible score is 40. A 
score of 8 is indicative of hazardous and harmful alcohol use, and possibly of alcohol 
dependence. Scores of 8–15 indicate a medium level and scores of 16 and above a
high level of alcohol problems. Babor et al. (2001) recommend a cutoff score of 7 for 
women and individuals over 65 years of age; Bradley et al. (1998) recommended an
even lower cutoff score of 4 points for women. For patients who are resistant, 
uncooperative, or noncommunicative, a clinical screening procedure (described by 
Babor et al., 2001) may be necessary. 
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Readiness Ruler 

Readiness Ruler: How Ready Are You To Change Your Use of _____________? 

Circle one answer for each type of drug. 

Types of Drugs 
Answer: Not Ready to Change (1–3), Unsure (3–5), 
Ready to Change (5–8), Trying to Change (8–10) 
Or: I don’t use 
this type of drug 
Alcohol 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Tobacco 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Marijuana/ 
Cannabis 
1 2 3 4 5 6 7 8 9 10 
Don’t Use 
Tranquilizers 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Sedatives/ 
Downers 
1 2 3 4 5 6 7 8 9 10 
Don’t Use 
Steroids 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Stimulants/ 
Uppers 
1 2 3 4 5 6 7 8 9 10 
Don’t Use 
Cocaine 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Hallucinogens 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Opiates 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Inhalants 1 2 3 4 5 6 7 8 9 10 Don’t Use 
Other Drugs 1 2 3 4 5 6 7 8 9 10 Don’t Use 
http://casaa.unm.edu/inst.html; click on Readiness Ruler 
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Buprenorphine Treatment Checklist 
1. Does the patient have a diagnosis of opioid dependence? 
2. Are there current signs of intoxication or withdrawal? Is there a risk for 
severe withdrawal? 
3. Is the patient interested in buprenorphine treatment? 
4. Does the patient understand the risks and benefits of buprenorphine treatment? 
5. Can the patient be expected to adhere to the treatment plan? 
6. Is the patient willing and able to follow safety procedures? 
7. Does the patient agree to treatment after a review of the options? 
8. Can the needed resources for the patient be provided (either on- or offsite)? 
9. Is the patient psychiatrically stable? Is the patient actively suicidal or homicidal; 
has he or she recently attempted suicide or homicide? Does the patient exhibit 
emotional, behavioral, or cognitive conditions that complicate treatment? 
10. Is the patient pregnant?  
11. Is the patient currently dependent on or abusing alcohol? 
12. Is the patient currently dependent on benzodiazepines, barbiturates, or other 
sedative-hypnotics? 
13. What is the patient’s risk for continued use or continued problems? Does the 
patient have a history of multiple previous treatments or relapses, or is the 
patient at high risk for relapse to opioid use? Is the patient using other drugs? 
14. Has the patient had prior adverse reactions to buprenorphine? 
15. Is the patient taking other medications that may interact with buprenorphine? 
16. Does the patient have medical problems that are contraindications to 
buprenorphine treatment? Are there physical illnesses that complicate 
treatment? 
17. What kind of recovery environment does the patient have? Are the patient’s 
psychosocial circumstances sufficiently stable and supportive? 
18. What is the patient’s level of motivation? What stage of change characterizes 
this patient? 
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Mental Health Screening Form-III 

Instructions: In this program, we help people with all their problems, not just 
their addictions. This commitment includes helping people with emotional 
problems. Our staff is ready to help you to deal with any emotional problems you 
may have, but we can do this only if we are aware of the problems. Any information 
you provide to us on this form will be kept in strict confidence. It will not be 
released to any outside person or agency without your permission. If you do not 
know how to answer these questions, ask the staff member giving you this form for 
guidance. Please note, each item refers to your entire life history, not just your 
current situation, this is why each question begins - “Have you ever ....” 
1. Have you ever talked to a psychiatrist, psychologist, therapist, social worker, or 
counselor about an emotional problem?
□ YES □ NO 
2. Have you ever felt you needed help with your emotional problems, or have you 
had people tell you that you should get help for your emotional problems? 
□ YES □ NO 
3. Have you ever been advised to take medication for anxiety, depression, hearing 
voices, or for any other emotional problem? 
□ YES □ NO 
4. Have you ever been seen in a psychiatric emergency room or been hospitalized 
for psychiatric reasons? 
□ YES □ NO 
5. Have you ever heard voices no one else could hear or seen objects or things 
which others could not see? 
□ YES □ NO 
6.	  (a) Have you ever been depressed for weeks at a time, lost interest or pleasure 
in most activities, had trouble concentrating and making decisions, or thought 
about killing yourself?
□ YES □ NO 
(b) Did you ever attempt to kill yourself? 
□ YES □ NO 
7. Have you ever had nightmares or flashbacks as a result of being involved in 
some traumatic/terrible event? For example, warfare, gang fights, fire, domestic 
violence, rape, incest, car accident, being shot or stabbed?
□ YES □ NO 
8. Have you ever experienced any strong fears? For example, of heights, insects, 
animals, dirt, attending social events, being in a crowd, being alone, being in
places where it may be hard to escape or get help? 
□ YES □ NO 
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9. Have you ever given in to an aggressive urge or impulse, on more than one 
occasion, that resulted in serious harm to others or led to the destruction of 
property?
□ YES □ NO 
10.Have you ever felt that people had something against you, without them 
necessarily saying so, or that someone or some group may be trying to influence 
your thoughts or behavior?
□ YES □ NO 
11.Have you ever experienced any emotional problems associated with your sexual 
interests, your sexual activities, or your choice of sexual partner? 
□ YES □ NO 
12.Was there ever a period in your life when you spent a lot of time thinking and 
worrying about gaining weight, becoming fat, or controlling your eating? For 
example, by repeatedly dieting or fasting, engaging in much exercise to 
compensate for binge eating, taking enemas, or forcing yourself to throw up? 
□ YES □ NO 
13.Have you ever had a period of time when you were so full of energy and your 
ideas came very rapidly, when you talked nearly non-stop, when you moved 
quickly from one activity to another, when you needed little sleep, and believed 
you could do almost anything?
□ YES □ NO 
14.Have you ever had spells or attacks when you suddenly felt anxious, frightened, 
uneasy to the extent that you began sweating, your heart began to beat rapidly, 
you were shaking or trembling, your stomach was upset, you felt dizzy or
unsteady, as if you would faint?
□ YES □ NO 
15.Have you ever had a persistent, lasting thought or impulse to do something over 
and over that caused you considerable distress and interfered with normal 
routines, work, or your social relations? Examples would include repeatedly 
counting things, checking and rechecking on things you had done, washing and 
rewashing your hands, praying, or maintaining a very rigid schedule of daily 
activities from which you could not deviate. 
□ YES □ NO 
16.Have you ever lost considerable sums of money through gambling or had 
problems at work, in school, with your family and friends as a result of your 
gambling?
□ YES □ NO 
17.Have you ever been told by teachers, guidance counselors, or others that you 
have a special learning problem?
□ YES □ NO 
80
 Appendix D: Assessment Instruments
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Print client’s name: ___________________________________________________________ 
Program to which client will be assigned: _______________________________________ 
Name of admissions counselor: ________________________  Date: _________________ 
Reviewer’s comments: _________________________________________________________ 
Total Score: ____________ (each yes = 1 point) 
Source: Carroll, J. F. X., & McGinley, J. J. (2000). Project Return Foundation, Inc. 
This material may be reproduced or copied, in entirety, without permission. Available 
at http://www.asapnys.org/resources/mhscreen.pdf
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Stages of Change Readiness and Treatment Eagerness Scale 
(SOCRATES 8D) 
INSTRUCTIONS: Please read the following statements carefully. Each one 
describes a way that you might (or might not) feel about your drug use. For each 
statement, circle one number from 1 to 5 to indicate how much you agree or 
disagree with it right now. Please circle one and only one number for every 
statement. 
# Statement 
NO! 
Strongly 
Disagree 
No 
Disagree 
? 
Undecided 
or Unsure 
Yes 
Agree 
YES! 
Strongly 
Agree 
1. I really want to make changes in my use of drugs. 1 2 3 4 5 
2. Sometimes I wonder if I am an addict. 1 2 3 4 5 
3. If I don’t change my drug use soon, my problems 
are going to get worse. 
1 2 3 4 5 
4. I have already started making some changes in  
my use of drugs. 
1 2 3 4 5 
5. I was using drugs too much at one time, but I’ve 
managed to change that. 
1 2 3 4 5 
6. Sometimes I wonder if my drug use is hurting 
other people.
1 2 3 4 5 
7. I have a drug problem. 1 2 3 4 5 
8. I’m not just thinking about changing my drug  
use, I’m already doing something about it.
1 2 3 4 5 
9. I have already changed my drug use, and I am 
looking for ways to keep from slipping back to  
my old pattern. 
1 2 3 4 5 
10. I have serious problems with drugs. 1 2 3 4 5 
11. Sometimes I wonder if I am in control of my drug 
use. 
1 2 3 4 5 
12. My drug use is causing a lot of harm. 1 2 3 4 5 
13. I am actively doing things now to cut down or 
stop my use of drugs. 
1 2 3 4 5 
14. I want help to keep from going back to the drug 
problems that I had before. 
1 2 3 4 5 
15. I know that I have a drug problem. 1 2 3 4 5 
16. There are times when I wonder if I use drugs too 
much. 
1 2 3 4 5 
17. I am a drug addict. 1 2 3 4 5 
18. I am working hard to change my drug use. 1 2 3 4 5 
19. I have made some changes in my drug use, and I 
want some help to keep from going back to the 
way I used before. 
1 2 3 4 5 
Source: Miller, W. R., & Tonigan, J. S. (1996). Assessing drinkers’ motivation for change: The Stages of Change 
Readiness and Treatment Eagerness Scale (SOCRATES). Psychology of Addictive Behaviors, 10, 81–89.  
SOCRATES 8D and SOCRATES 8D Scoring Sheet. Available at Center on Alcoholism, Substance Abuse, and 
Addictions (CASAA), Assessment Instruments. http://casaa.unm.edu/inst/SOCRATESv8.pdf. Reprinted with 
permission. 
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SOCRATES Scoring Form (19-Item Version 8.0) 
Transfer the client’s answers from questionnaire (see note below): 
 Recognition 
1 _________ 
3 _________ 
7 _________ 
 10 _________ 
 12 _________ 
 15 _________ 
 17 _________ 
Ambivalence 
2 _________ 
5 _________
6 _________
9 _________
11 _________ 
14 _________
16 _________ 
19 _________
Taking Steps 
4 _________ 
8 _________ 
13 _________ 
18 _________ 
 
 
 
 
TOTALS: Recognition _________ Ambivalence _________ Taking Steps _________ 
Possible Range: Recognition (7–35), Ambivalence (4–20), Taking Steps (8–40) 
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SOCRATES Profile Sheet (19-Item Version 8A) 

INSTRUCTIONS: From the SOCRATES Scoring Form (19-Item Version) transfer 
the total scale scores into the empty boxes at the bottom of the Profile Sheet. Then 
for each scale, CIRCLE the same value above it to determine the decile range. 
DECILE SCORES Recognition Ambivalence Taking Steps
90 Very High 19–20 39–40 
80 18 37–38 
70 High 35 17 36 
60 34 16 34–35 
50 Medium 32–33 15 33 
40 31 14 31–32 
30 Low 29–30 12–13 30 
20 27–28 9–11 26–29 
10 Very Low 7–26  4–8 8–25 
RAW SCORES
(from Scoring 
Sheet) 
Re= Am= Ts= 
These interpretive ranges are based on a sample of 1,726 adult men and women
presenting for treatment of alcohol problems through Project MATCH. Note that 
individual scores are therefore being ranked as low, medium, or high relative to 
people already presenting for alcohol treatment. 
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Clinical Opiate Withdrawal Scale (COWS) 

For each item, circle the number that best describes the patient’s signs or 
symptoms. Rate just on the apparent relationship to opiate withdrawal. For 
example, if heart rate is increased because the patient was jogging just prior to 
assessment, the increased pulse rate would not add to the score.  
Patient Name: Date: Time: 
Reason for this assessment: 
1. Resting pulse rate: ______ beats/minute 
Measured after the patient is sitting or lying for 
one minute. 
0 Pulse rate 80 or below 
1 Pulse rate 81–100 
2 Pulse rate 101–120 
4 Pulse rate greater than 120 
7. GI upset: over last half hour 
0 No GI symptoms 
1 Stomach cramps 
2 Nausea or loose stool 
3 Vomiting or diarrhea 
5 Multiple episodes of diarrhea or vomiting 
2. Sweating: over past half hour not accounted 
for by room temperature of patient activity 
0 No reports of chills or flushing 
1 Subjective reports of chills or flushing 
2 Flushed or observable moisture on face 
3 Beads of sweat on brow or face 
4 Sweat streaming off face 
8. Tremor: observation of outstretched hands 
0 No tremor 
1 Tremor can be felt, but not observed 
2 Slight tremor observable 
4 Gross tremor or muscle twitching 
3. Restlessness: observation during assessment 
0 Able to sit still 
1 Reports difficulty sitting still, but is able to do so 
3 Frequent shifting or extraneous movements of 
legs/arms 
5 Unable to sit still for more than a few seconds 
9. Yawning: observation during assessment 
 
4. Pupil size 
0 Pupils pinned or normal size for room light 
1 Pupils possibly larger than normal for room light 
2 Pupils moderately dilated 
5 Pupils so dilated that only the rim of the iris is 
visible 
10. Anxiety or irritability 
5. Bone or joint aches: if patient was having pain 
previously, only the additional component 
attributed to opiate withdrawal is scored. 
0 Not present 
1 Mild diffuse discomfort 
2 Patient reports severe diffuse aching of 
joints/muscles 
4 Patient is rubbing joints or muscles and is unable 
to sit still because of discomfort 
6. Runny nose or tearing: not accounted for by 
cold symptoms or allergies 
0 Not present 
1 Nasal stuffiness or unusually moist eyes 
2 Nose running or tearing 
4 Nose constantly running or tears streaming 
down cheeks 
0 No yawning 
1 Yawning once or twice during assessment 
2 Yawning three or more times during assessment
4 Yawning several times/minute 
11. Gooseflesh skin 
0 Skin is smooth 
3 Piloerection of skin can be felt or hairs standing 
up on arms 
5 Prominent piloerection 
0 None 
1 Patient reports increasing irritability or 
anxiousness 
2 Patient obviously irritable, anxious 
4 Patient so irritable or anxious that participation 
in the assessment is difficult 
Total Score: _______________________ 
[The total score is the sum of all 11 items.] 
Initials of person completing assessment: _______ 
Score: 5–12 = Mild; 13–24 = Moderate; 25–36 = Moderately severe; >36 = Severe withdrawal 
Source: California Society for Addiction Medicine. http://www.csam-asam.org/pdf/misc/COWS.doc. Reprinted 
with permission from the California Society of Addiction Medicine. 
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Subjective Opiate Withdrawal Scale (SOWS) 

Instructions: Answer the following statements as accurately as you can. Circle the 
answer that best fits the way you feel now. 
0 = not at all 
1 = a little 
2 = moderately
3 = quite a bit
4 = extremely 
Statement Not at all A little Moderately Quite a bit Extremely 
1. I feel anxious. 0 1 2 3 4 
2. I feel like yawning. 0 1 2 3 4 
3. I’m perspiring. 0 1 2 3 4 
4. My eyes are tearing. 0 1 2 3 4 
5. My nose is running. 0 1 2 3 4 
6. I have goose flesh. 0 1 2 3 4 
7. I am shaking. 0 1 2 3 4 
8. I have hot flashes. 0 1 2 3 4 
9. I have cold flashes. 0 1 2 3 4 
10. My bones and muscles ache. 0 1 2 3 4 
11. I feel restless. 0 1 2 3 4 
12. I feel nauseous. 0 1 2 3 4 
13. I feel like vomiting. 0 1 2 3 4 
14. My muscles twitch. 0 1 2 3 4 
15. I have cramps in my
stomach. 
0 1 2 3 4 
16. I feel like shooting up now. 0 1 2 3 4 
The Subjective Opiate Withdrawal Scale (SOWS) consist of 16 symptoms rated in intensity by 
patients on a 5 point scale of intensity as follows: 0 = not at all, 1 = a little, 2 = moderately, 3 = quite 
a bit, 4 = extremely. The total score is a sum of item ratings, and ranges from 0 to 64. 
Source: Reprinted from Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & 
Kanof, P. D. (1987). Two new rating scales for opiate withdrawal. American Journal of Drug and 
Alcohol Abuse, 13(3), 293–308. Table 1 on page 296. Reprinted by permission of the publisher, 
Taylor & Francis, Ltd., http://www.tandf.co.uk/journals. 
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The Clinical Institute Narcotic Assessment (CINA) 

Scale for Withdrawal Symptoms 

The Clinical Institute Narcotic Assessment (CINA) Scale measures 11 signs and 
symptoms commonly seen in patients during narcotic withdrawal. This can help to 
gauge the severity of the symptoms and to monitor changes in the clinical status 
over time. To view the CINA scale, visit 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.section.72871 (CSAT, 2004). 
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Addiction Research Foundation Clinical Institute for Withdrawal 
Assessment (CIWA-Ar) 
Patient: Date: Time: 
(24 hour clock, midnight = 
00:00) 
NAUSEA AND VOMITING—Ask “Do you feel 
sick to your stomach? Have you vomited?” 
Observation. 
0 no nausea and no vomiting 
1 mild nausea with no vomiting 
2 
3 
4 intermittent nausea with dry heaves 
5 
6 
7 constant nausea, frequent dry heaves and 
vomiting 
TACTILE DISTURBANCES—Ask “Have you any 
itching, pins and needles sensations, any 
burning, any numbness, or do you feel bugs 
crawling on or under your skin?” 
Observation. 
0 none 
1 very mild itching, pins and needles, burning 
or numbness 
2 mild itching, pins and needles, burning or 
numbness 
3 moderate itching, pins and needles, burning 
or numbness 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
TREMOR—Arms extended and fingers spread 
apart. 
Observation. 
0 no tremor 
1 not visible, but can be felt fingertip to 
fingertip 
2 
3 
4 moderate, with patient’s arms extended 
5 
6 
7 severe, even with arms not extended 
AUDITORY DISTURBANCES—Ask “Are you 
more aware of sounds around you? Are they 
harsh? Do they frighten you? Are you hearing 
anything that is disturbing to you? Are you 
hearing things you know are not there?” 
Observation. 
0 not present 
1 very mild harshness or ability to frighten  
2 mild harshness or ability to frighten  
3 moderate harshness or ability to frighten 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
PAROXYSMAL SWEATS—Observation. 
0 no sweat visible 
1 barely perceptible sweating, palms moist 
2 
3 
4 beads of sweat obvious on forehead 
5 
6 
7 drenching sweats 
VISUAL DISTURBANCES—Ask “Does the light 
appear to be too bright? Is its color different? 
Does it hurt your eyes? Are you seeing anything 
that is disturbing to you? Are you seeing things 
you know are not there?” 
Observation. 
0 not present 
1 very mild sensitivity 
2 mild sensitivity 
3 moderate sensitivity 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
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ANXIETY—Ask “Do you feel nervous?” 
Observation. 
0 no anxiety, at ease 
1 mildly anxious 
2 
3 
4 moderately anxious, or guarded, so anxiety 
is inferred 
5 
6 
7 equivalent to acute panic states as seen in 
severe delirium or acute schizophrenic 
reactions. 
HEADACHE, FULLNESS IN HEAD—Ask “Does 
your head feel different? Does it feel like there 
is a band around your head?” Do not rate for 
dizziness or lightheadedness. Otherwise, rate 
severity. 
0 not present 
1 very mild 
2 mild 
3 moderate 
4 moderately severe 
5 severe 
6 very severe 
7 extremely severe 
AGITATION—Observation. 
0 normal activity 
1 somewhat more than normal activity 
2 
3 
4 moderately fidgety and restless 
5 
6 
7 paces back and forth during most of the 
interview, or constantly thrashes about 
ORIENTATION AND CLOUDING OF 
SENSORIUM—Ask “What day is this? Where are 
you? Who am I?” 
0 oriented and can do serial additions 
1 cannot do serial additions or is uncertain 
about date 
2 disoriented for date by no more than 2 
calendar days 
3 disoriented for date by more than 2 calendar 
days 
4 disoriented for place and/or person 
 Total CIWAr-Score _____________________
Rater’s Initials _____________________ 
Maximum Possible Score  67 
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This scale is not copyrighted and can be reproduced freely. 

Source: Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, D., & Sellers, E. M. (1989). Assessment of 

alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). 

British Journal of Addiction, 84(11), 1353–1357. 
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Suggested Questions for Patient Interview 

Buprenorphine Treatment 

Kathleen Thompson-Gargano, R.N., A.D.N. (October 2006) 
Prior to Induction: 
What opiates do you use? 
Frequency, route, and amount 
What are your first symptoms of withdrawal? 
Will you be able to commit to appointments? 
Is there someone who can drive you in for your first 
appointment? 
Give specific appointment time and let patient know s/he should plan to be here for 2 hours on the 
first day only. 
Nursing History and Assessment: 
When was the first time you used any substances of 
any kind including cigarettes, pot and alcohol? 
What was the next substance and at what age?  
Tell me about your current use, all substances, 
amounts, frequency, and route of administration.  
Have you ever shared a needle at any time?  
Tell me about your past treatment experiences. 
What was your longest clean time? 
What happened to make you go back to using? 
What was the most you ever used in a day? 
Have you ever overdosed?  
Have you ever been admitted to the ED or hospital 
because of your drug use? 
Have you ever been arrested or incarcerated?  
Are you currently on probation? 
What made you decide to come for treatment at this 
time? 
On a scale from 1 to 10, 1 being you are forced into 
coming here by court or a family member, and 10 
being your life depends on it, where are you? 
Any family members addicted to substances of any 
kind? 
Tell me about your living situation? 
Does anyone you live or work with use opiates or 
cocaine? 
Are you scheduled to have surgery in the near future? 
Are you scheduled to go out of town or on vacation in 
the next 6 months? 
95 

  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Appendix D: Assessment Instruments
Principles of Effective Addictions Treatment (NIDA, 1999) 

1.	 No single treatment is appropriate for all individuals. Matching treatment
settings, interventions, and services to each individual’s particular problems and 
needs is critical to his or her ultimate success in returning to productive 
functioning in the family, workplace, and society.  
2.	 Treatment needs to be readily available. Because individuals who are 
addicted to drugs may be uncertain about entering treatment, taking advantage 
of opportunities when they are ready for treatment is crucial. Potential 
treatment applicants can be lost if treatment is not immediately available or is
not readily accessible. 
3.	 Effective treatment attends to multiple needs of the individual, not just 
his or her drug use. To be effective, treatment must address the individual’s 
drug use and any associated medical, psychological, social, vocational, and legal 
problems. 
4.	 Treatment plan must be assessed continually to ensure that it meets 
changing needs. In addition to medication, the person may require varying 
combinations of services and treatment components, including: 
• Counseling or psychotherapy;
• Medical services;  
• Family therapy;
• Parenting instruction;
• Vocational rehabilitation; AND
• Social and legal services. 
5.	 Remaining in treatment for an adequate period of time is critical for 
treatment effectiveness. 
• Appropriate duration depends on problems and needs.  
• For most patients, the threshold of significant improvement is about 3 months 
in treatment. 
• Additional treatment can produce further progress toward recovery.  
• People often leave treatment prematurely, so plan strategies to engage and 
keep patients in treatment.
6.	 Counseling (individual/group) and other behavioral therapies are 
critical components of effective treatment. In therapy, patients:
• Address motivation;
• Build skills to resist drug use;  
• Replace drug-using activities with constructive and rewarding nondrug-using 
activities;
• Improve problemsolving abilities;
• Work on interpersonal relationships;  
• Improve family and community functioning. 
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7.	 Medications are an important element of treatment for many patients, 
especially when combined with counseling and other behavioral 
therapies.
• Opioid replacement therapy can be very effective in helping individuals 

stabilize their lives and reduce their drug use. 

• Both behavioral treatments and medications can be critically important, 

especially for patients with mental disorders.  

8.	 Addicted or drug-abusing individuals with coexisting mental disorders 
should have both disorders treated in an integrated way.
• Substance use disorders (SUDs) and mental disorders often co-occur;  
• Patients presenting for either condition should be assessed and treated for the 
co-occurrence of the other type of disorder. 
9.	 Medical detoxification is only the first stage of addiction treatment and 
by itself does little to change long-term drug use.  
• Detox safely manages acute physical symptoms of withdrawal; 
• Detox alone is rarely sufficient to achieve long-term abstinence;  
• Strongly indicated precursor to effective drug addiction treatment for some 
individuals. 
10.Treatment does not need to be voluntary to be effective.
• Strong motivation can facilitate the treatment process;  
• Sanctions or enticements in the family, employment setting, or criminal justice 
system can increase significantly: 
–Treatment entry and retention rates; and 
–Success of drug treatment interventions. 
11.Possible drug use during treatment must be monitored continuously. 
• It is not unusual for lapses to occur during treatment.  
• Objective monitoring (urinalysis/other tests) helps patients withstand urges to 
use. 
• Monitoring can provide early evidence of drug use so that the treatment plan 
can be adjusted.
• Feedback to patients who test positive for illicit drug use is an important 
element of monitoring. 
12.Treatment providers should assess and counsel individuals about 
HIV/AIDS, hepatitis B and C, tuberculosis, and other infectious 
diseases. 
• Counsel to avoid high-risk behavior.
• Counsel to help people who are already infected manage their illness. 
13.Recovery from drug addiction can be a long-term process and 
frequently requires multiple episodes of treatment.  
• As with other chronic illnesses, relapses can occur during or after successful 
treatment episodes.
• Individuals may require prolonged treatment and multiple episodes of 
treatment to achieve long-term abstinence and fully restored functioning.  
• Participation in self-help support programs during and following treatment 
often is helpful in maintaining abstinence. 
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